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ABSTRACT OF THESIS 
 
 
 
 
ASSESSMENT OF BOVINE VASCULAR SEROTONIN RECEPTOR POPULATIONS 
AND TRANSPORT OF ERGOT ALKALOIDS IN THE SMALL INTESTINE 
 
 Prior work using a contractility bioassay determined that the serotonin (5-HT) 
receptor subtype 5-HT2A is present in bovine lateral saphenous veins and plays a role in 
ergot alkaloid-induced vascular contraction in steers grazing endophyte-infected 
(Epichloë coenophiala) tall fescue (Lolium arundinaceum). A study was conducted to 
determine what 5-HT receptors are involved in vasoconstriction of bovine gut 
vasculature. The findings of this study indicate that 5-HT2A is present and may play a role 
in ergot alkaloid induced vasoconstriction. A second study was conducted to determine if 
ergot alkaloids were transported in the small intestine. The active transporter, peptide 
transporter 1 (PepT1), was evaluated for its role in the transport of various concentrations 
of ergot alkaloids across Caco-2 cell monolayers. Results indicate that CEPH, ERT, EXT, 
and LSA do move across Caco-2 cell monolayers, but appear to utilize PepT1 at larger 
concentrations. Overall, the demonstrated presence of 5-HT2A receptors in the bovine gut 
vasculature established a potential for vascular interference by ergot alkaloids entering 
the bloodstream through transepithelial absorption. 
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CHAPTER ONE: INTRODUCTION 
Grasses that are important to animal agriculture can become infected with 
endophytic fungi some of which produce ergot alkaloids in the tissues of their plant hosts. 
Ergot alkaloids are secondary metabolites and mycotoxins that are produced by numerous 
species of fungi belonging to the genera Claviceps and Epichloë (Strickland et al., 2011). 
One host grass that is beneficial as a pasture-based feed source is tall fescue (Lolium 
arundinaceum) (Strickland et al., 2011). Tall fescue has numerous desirable traits as a 
forage for cattle and other domestic herbivores, but the ergot alkaloids that are produced 
lead to the livestock disorder called fescue toxicosis. Some symptoms include rough hair 
coat, excessive salivation, elevated body temperature, and dry gangrene in the extremities 
(Strickland et al., 2011). Such symptoms are vague and could also point to other 
maladies. 
At present, the site(s) and mechanism(s) of ergot alkaloid absorption have not 
been fully described. Some studies have indicated that some absorption and metabolism 
of alkaloids occurs before reaching the duodenum (Westendorf et al., 1993; Schumann et 
al., 2009) and before excretion of feces (Schumann et al., 2009). While there are studies 
linking the absorption of ergot alkaloids across ruminant gastric tissues (Hill et al., 2001; 
De Lorme et al., 2007) there is not much information available concerning the absorption 
and transport of ergot alkaloids across the small intestine.  
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CHAPTER TWO: LITERATURE REVIEW 
Introduction 
 Tall fescue (Lolium arundinaceum) is a perennial grass and is one of the most 
abundant forage crops in the United States (Jackson et al., 1984; Buckner et al., 1979). It 
is the one of the most widely used cool-season grasses in the southeastern region and 
predominates in the transition zone between the northern and southern regions of the 
eastern United States (Williams et al., 1984; Paterson et al., 1995), also referred to as the 
fescue suitability zone (Hannaway et al., 2009). It was discovered on a Kentucky farm in 
the 1930s and marketed as ‘Kentucky 31’ in 1942 (Fergus & Buckner, 1972; Bacon, 
1995).  Tall fescue became prevalent in an area that needed a quality forage as it 
exhibited numerous desirable traits such as increased hardiness, resistance to pests, high 
adaptability, and extended grazing season (Stuedemann & Hoveland, 1988; Bacon, 
1995). Despite all of the positive traits tall fescue exhibited, it became evident that 
livestock were not thriving when grazing tall fescue, developing unthrifty appearances 
and general reduced performance (Stuedemann & Hoveland, 1988). These symptoms 
were termed fescue toxicosis and have been associated with the endophytic fungus 
Neotyphodium coenophialum (Bacon et al., 1977) later reclassified as Epichloë 
coenophiala (Leuchtmann et al., 2014). 
Symbiosis with the Endophyte  
The distribution of tall fescue has been attributed to its symbiotic relationship 
with the endophytic fungus E. coenophiala (Glenn et al., 1996; Strickland et al., 2011). E. 
coenophiala is located throughout the plant but is of highest concentration around the 
crown meristem during vegetative periods (Schardl & Phillips, 1997) and in the side 
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branches of flower heads during the reproductive stage (Bacon & Siegel, 1988). Bacon et 
al. (1977) first reported the presence of the endophyte from tall fescue pastures in 
Georgia. Cattle grazing on E+ (endophyte positive) pastures displayed fescue toxicosis 
symptoms while cattle that were housed and fed E+ showed no symptoms (Bacon et al., 
1977). This phenomenon was also observed in a study conducted by Schmidt et al. 
(1982). Cattle that were fed E- (endophyte negative) hay and seed showed no symptoms 
of fescue toxicosis while cattle fed E+ hay and seed exhibited symptoms (Schmidt et al., 
1982). Both studies imply that there is a correlation between fescue toxicosis and 
endophyte presence. 
 The endophyte cannot survive without a host and contributes toxic secondary 
metabolites to its host that allows protection against ingestion by herbivores and other 
invertebrate agricultural pests (Schardl & Phillips, 1997; Rowan et al., 1986) amongst 
other benefits. The host plant benefits by gaining increased drought tolerance, root 
growth, nematode tolerance, and improved germination (Arachavaleta et al., 1992; 
Norman, 2008). Arachavaleta et al. (1989) conducted a study in which 75% of E- tall 
fescue plants survived during extreme drought conditions, but 100% of E+ tall fescue 
plants survived and displayed greater regrowth once harvested. This implies that the 
endophyte does indeed improve plant hardiness.  
Tall Fescue Toxicosis 
Signs and Symptoms 
 Once considered a superior forage, tall fescue developed a reputation as an 
inferior forage based on production issues and poor animal performance (Stuedemann & 
Hoveland, 1988). Animals grazing on tall fescue may exhibit three conditions: fat 
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necrosis, fescue foot, and tall fescue toxicosis (Paterson et al., 1995). Fescue foot is 
recognized by symptoms such as swelling around the fetlock and hoof, dry gangrene at 
the tips of the tail and ears, and lameness (Cunningham, 1948). In advanced cases, 
animals that are affected by fescue foot may lose their hooves to sloughing which is an 
effect of ergot alkaloids on blood vessels (Strickland et al., 2009). Ergot alkaloids 
damage the cells that line blood vessels, enhance blood clotting, and lead to 
vasoconstriction of the lumens of blood vessels (Tor-Agbidye et al., 2001). Fat necrosis is 
not as obvious as fescue foot besides poor performance and an unthrifty appearance. This 
is due to necrotic fat constricting internal organs (Strickland et al., 2009).  
Fat necrosis and fescue foot are acute issues of concern to producers but fescue 
toxicosis is a more common and chronic problem that results in higher economic losses 
(Schmidt & Osborn, 1993). Tall fescue toxicosis is also known as fescue toxicosis, 
summer slump, or summer syndrome due to the unthrifty appearance and poor 
performance of the animal during the summer months (Schmidt & Osborn, 1993). Fescue 
toxicosis is problematic within the fescue suitability zone (Hannaway et al., 2009) and is 
related to high temperatures rather than an increase of toxic compounds during warmer 
months (Hemken et al., 1984). Signs and symptoms are usually not overly severe and are 
typically not recognized by producers until damage is already done. Issues from grazing 
on tall fescue pastures, such as reduced conception rates and decreased calf weight gains, 
have resulted in economic losses estimated around $609 million annually (Paterson et al., 
1995; Hoveland, 1993). When taking into account the effects on the small ruminant and 
equine industries, combined losses attributed to fescue toxicosis exceed $1 billion 
(Strickland et al., 2011). 
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Causative Agent: Secondary Metabolites 
The symbiotic relationship between tall fescue and endophyte bestows a 
competitive edge to the plant by fungal production of biologically active secondary 
metabolites. Numerous alkaloids were isolated from tall fescue and some proved to be 
biologically active (Bacon, 1995). Alkaloids in E+ tall fescue include the 
pyrrolopyrazine, peramine, the pyrrolizidines (lolines), and the ergot alkaloids (ergoline 
derivatives such as clavines, lysergic acid amides, and peptide alkaloids) (Figure 2.1).  
Pyrrolopyrazines  
 Perennial ryegrass (Lolium perenne) that is infected with the endophytic fungus 
Epichloë festucae var. lolii is resistant to a diverse number of insect species, including the 
Argentine stem weevil (Listronotus bonariensis), due to the pyrrolopyrazine peramine 
(Rowan et al., 1986). Biosynthetically, it appears that peramine is derived from the 
cyclization of the amino acids arginine and proline (Rowan et al., 1986). Rowan et al. 
(1986) isolated peramine through ethanol extraction, solvent partitioning, repeated 
chromatography, and analysis by high resolution mass spectroscopy. It appears that 
peramine is produced continuously by the endophyte, but does not accumulate in older 
plant tissues (Koulman et al., 2006). Using a linear ion trap mass spectrometer, Koulman 
et al. (2006) developed a highly sensitive method to analyze peramine and located 
peramine in the cut leaf fluid of all grass-endophyte associations analyzed, including tall 
fescue. However, peramine was not found in the guttation fluid of all grass-endophyte 
associations. Lolines and ergot alkaloids were found in the guttation fluid in some grass-
endophyte associations. This indicates that peramine and other fungal alkaloids were 
mobilized into plant fluids by the host plant. Siegel et al. (1990) showed that peramine 
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and the ergopeptine, ergovaline, were detected in 66% and 60% of endophyte-infected 
grasses. While peramine and ergovaline are produced in similar quantities, they are 
produced independently of one another meaning that breeding tall fescue with reduced 
ergovaline and toxicity to livestock does not affect insect resistance from peramine 
(Roylance et al., 1994).  
Pyrrolizidines (Lolines) 
 Pyrrolizidines, or lolines (saturated 1-aminopyrrolizidines with an oxygen bridge), 
are the most abundant alkaloids present in tall fescue and act as insecticides when 
produced in symbioses with Epichloë species and grasses, particularly Lolium and 
Festuca (Blankenship et al., 2001).  Prior to 2001, it was unknown if lolines were of plant 
origin or of fungal origin. Porter (1994) reported that lolines were not observed in fungal 
cultures. Using GC-MS and 13C NMR spectroscopic analyses, Blankenship et al. (2001). 
demonstrated that three of the loline alkaloids in plant tissues (loline, N-acetylnorloline, 
and N-formylloline were produced by the fungal endophyte N. uncinatum under certain 
minimal medium conditions. The structure of lolines consists of a saturated necine ring 
with –NRR’ substituent at Cl and an oxygen bridge between carbon 2 and carbon 7 
(Blankenship et al., 1991; Yates et al., 1990; Powell & Petroski, 1992). Bush et al. (1993) 
suggested that lolines are biosynthetically derived from spermine or spermidine. Loline 
alkaloids are distributed throughout the plant and offer protection to the plant in the form 
of broad-spectrum insecticides (Dahlman et al., 1997). However, lolines do not appear to 
be as toxic to mammalian species although activity has been noted in mammalian tissues 
and small mammals (Bush et al., 1993). Immunosuppressive effects have been observed 
in mouse feeding trials (Dew et al., 1990). It had been suggested that lolines may be 
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involved in vasoconstriction and may utilize α2-adrenergic, serotonin, or D2 dopamine 
receptors (Larson et al., 1995; Strickland et al., 1996). However, Klotz et al. (2008) 
demonstrated that bovine lateral saphenous veins did not show a contractile response 
when exposed to N-acetyl loline. 
Ergot Alkaloids  
Although concentrations of ergot alkaloids are lower than that of lolines, ergot 
alkaloids appear to impact mammals much more significantly. Ergot alkaloids are 
compounds that contain an ergoline ring (Bush et al., 1997) that is a component of 
lysergic acid, an intermediate compound produced when ergot alkaloids are degraded 
(Merill et al., 2007, De Lorme et al, 2007; Norman, 2008). The major classes of ergot 
alkaloids are the clavines, lysergic acid amides, and ergopeptines (Porter, 1995; Norman, 
2008). The most prevalent member of the ergopeptine class is ergovaline (Yates et al., 
1985; Yates & Powell, 1988) and is suspected to be the causative agent behind fescue 
toxicosis.  Low concentrations of ergovaline are enough to cause fescue toxicosis in heat 
stressed animals (Cornell, 1990). However, a single alkaloid or group of alkaloids has not 
been definitively identified as the primary cause of fescue toxicosis.  
Endocrine Changes 
Hormones that are associated with metabolic rate regulation include 
triiodothyronine (T3), cortisol, and thyroxine (T4). Studies have shown that E+ does not 
alter hormone profiles (Fiorite et al., 1991; Hurley et al., 1980; Aldrich et al., 1993). One 
consistent indicator of fescue toxicosis is decreased serum prolactin (Paterson et al., 
1995; Elsasser and Bolt, 1987; Schillo et al., 1988). Ergot alkaloids have been identified 
as potential agents in alteration of the production of numerous pituitary hormones (Porter 
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et al., 1990; Browning et al., 1997) and are influential in prolactin secretion. Prolactin is a 
protein hormone that is secreted by the adenohypophysis (anterior pituitary gland) with 
secretion and inhibition being mediated by dopamine. Ergot alkaloids may be responsible 
for decreased levels of serum prolactin by binding to D2 dopamine receptors and 
producing a second messenger response that depresses levels of prolactin (Larson et al., 
1995; Hurley et al., 1980; Elsasser and Bolt, 1987).   
It has been found that phenothiazine may enhance prolactin secretion as it acts as 
a dopamine antagonist (Boling et al., 1989). Boling et al. (1989) conducted two 
experiments to determine the effects of phenothiazine and temperature on prolactin 
concentrations and growth of calves that consumed high endophyte or low endophyte tall 
fescue. It was found that while phenothiazine may reduce decreases in prolactin from a 
high endophyte tall fescue diet, reductions might also depend on ambient temperatures 
(Boling et al., 1989). Other dopamine antagonists such as haloperidol and domperidone 
(Paterson et al., 1995; Bolt et al., 1983; Boling et al., 1989; Cross et al., 1995) have been 
tested as possible pharmaceuticals to treat fescue toxicosis, but the actual mechanism 
behind fescue toxicity has not been identified conclusively. 
Alkaloid Mode of Action  
Catecholamines 
Ergot alkaloids found in E+ act similarly to dopamine and other catecholamines 
such as serotonin (5-HT), epinephrine (EP), and norepinephrine (NE) and can cause 
vasoconstriction by binding biogenic amine receptors (Figure 2.2). Catecholamines have 
major roles in metabolic pathways such as lipolysis, glycogenolysis, and contraction-
relaxation of smooth muscles (Norman, 2008). Specifically, catecholamines interact with 
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receptors such as α-2 adrenergic receptor, serotonergic-2 receptor, and dopaminergic-2 
receptors (Norman, 2008). These receptors exist throughout the central nervous system, 
blood vessels, and in the gastrointestinal tract (Oliver, 1997). Sibley and Creese (1983) 
investigated the interactions of ergot alkaloids with bovine anterior pituitary D-2 
dopamine receptors utilizing radioligand binding techniques and computer modeling 
technologies. Ergolines interacted with receptors in an agonist-specific way and exhibited 
competition curves which were divided into high and low affinity components (Sibley & 
Creese, 1983). Only the low-affinity compounds were observed when in the presence of 
guanine nucleotides, suggesting that guanine nucleotides convert high affinity 
compounds to low affinity compounds as guanine nucleotides regulate binding at specific 
dopamine receptors (Creese et al., 1979). In contrast, ergot alkaloids that contained a 
cyclic peptide side chain (ergopeptines) exhibited competition curves that were 
monophasic and unaffected by guanine nucleotides (Sibley & Creese, 1983). This implies 
that ergopeptines have similar binding properties of antagonist ligands. Ergot alkaloid 
action at the site of these receptors can cause metabolic changes by alteration of 
homeostatic mechanisms (Strickland et al., 1993). 
Blood Flow and Ergot Alkaloid Vasoactivity 
Epinephrine and NE are involved in the control of blood flow in the body and 
play a role in the regulation of vasoconstriction. Changes in peripheral blood flow are 
related to the ability to dissipate body heat. Plasma EP and NE were not altered after E+ 
was consumed (Henson et al., 1987; Elsasser & Bolt, 1987). Henson et al. (1987) showed 
that hypothalamic and pituitary levels of EP, NE, and dopamine levels were unchanged. 
This indicates that an alternate mechanism is involved at the receptor level.  
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Body heat regulation can occur through skin vaporization and increased 
respiration rates. The inability to dissipate body heat may be a result of decreased blood 
flow. Rhodes et al. (1991) showed that cattle that consumed an E+ diet displayed a 50% 
reduction in blood flow to the skin which is characteristic of heat stress symptoms that 
accompany fescue toxicosis. Aiken et al. (2009) also observed vasoconstriction as 
luminal areas of caudal arteries were restricted 27 and 51 hours after heifers consumed a 
diet of 0.39 μg ergovaline/kg body weight or 0.79 μg ergovaline/kg body weight. 
Using radiolabeled microspheres, Rhodes et al. (1991) showed that cattle on an 
E+ diet at high ambient temperatures showed reduced blood flow to the gastrointestinal 
tract. However, Harmon et al. (1991) conducted a study in which the results contradicted 
that of Rhodes et al. (1991). Harmon et al. (1991) found that there was no effect of an E+ 
diet on the flow of blood through the portal vein. Discrepancies could be explained by 
amounts of E+ fescue fed to animals, by differences in ambient temperatures, species 
differences, and diet differences.  
Egert et al. (2014) conducted an experiment in which branches of mesenteric 
artery (MA) and mesenteric vein (MV) were collected from steers dosed with either E+ 
or E- fescue seed in order to determine if prior exposure to E+ tall fescue seed affected 
vasoactivity. Tissues were exposed to ergocryptine, ergtamine, ergocristine, ergocornine, 
ergonovine, lysergic acid, ergovaline-containing tall fescue seed extract (EXT), and 5-
hydroxytryptamine (5-HT). Steers that were previously exposed to E+ seed had a smaller 
MA contractile response than E- steers to ergocryptine, ergotamine, ergocristine, 
ergocornine, ergonovine, EXT, and 5-HT. Steers with prior exposure to E+ seed had a 
smaller MV contractile response than E- steers to ergocryptine, ergotamine, ergocristine, 
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ergonovine, EXT, and 5-HT. There was no contractile response to lysergic acid in MV or 
MA. The EXT produced the most potent response in both MV and MA. This indicates 
that ergot alkaloids were vasoactive in the midgut and that steers previously exposed to 
E+ had diminished contractility. This suggests that prior dietary exposure to ergot 
alkaloids may alter nutrient absorption by decreasing blood flow. 
Foote et al. (2013) investigated the effects of ergot alkaloids on reticuloruminal 
epithelial blood flow and volatile fatty acid (VFA) absorption by washing the 
reticulorumen of steers on an E+ diet or E- diet in the presence of accumulating levels of 
ergot alkaloids in steers housed in thermoneutral and heat stressed conditions. Steers 
were exposed to a VFA-containing buffer incubated in the sequence: control, 1xEXT, and 
3xEXT.  There were two 30 min sampling periods: a 30 min incubation of a treatment 
buffer with no sampling and a 30 min incubation of the same treatment buffer with the 
addition of chromium-EDTA and deuterium oxide. Steers on the E+ diet exposed to heat 
stressed conditions decreased their feed intake. At heat stressed conditions, serum 
prolactin decreased in both groups with no difference in 1xEXT and 3xEXT treatment 
groups. An interaction between the seed treatment and buffer treatment was preset, 
indicating that the E+ seed treatment decreased reticuloruminal epithelial blood flow at 
thermoneutral conditions during the control incubation. Presence of EXT in the buffer 
decreased epithelial blood flow by at least 50% although there was no difference between 
steers exposed to 1xEXT and 3xEXT. At heat stressed conditions, there was a seed and 
buffer treatment interaction, indicating that reduced blood flow induced by incubating the 
EXT was larger for steers on the E- treatment. Time either increased or did not affect 
blood flow or VFA flux when an additional experiment was conducted to determine the 
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time effect on blood flow and VFA flux. This indicated that differences were due to ergot 
alkaloid presence in the rumen. 
Foote et al. (2014) conducted a study using Holstein steers to determine the 
effects of EXT on total, passive, and facilitated acetate and butyrate flux across ruminal 
tissue and barrier function. Isolated tissues were mounted on Ussing chambers and 
exposed to a vehicle control, low EXT, and high EXT. Results indicated that there was no 
effect of acute exposure on total, passive, and facilitated flux of acetate and butyrate 
across rumen epithelium. Barrier function was measured by inulin flux, which was not 
affected by EXT treatment, indicating no change in barrier function due to ergot alkaloid 
exposure. Ergovaline was found in serosal buffer of the high EXT treatment indicating 
that ergovaline has the potential to be absorbed via the rumen, contributing to reduced 
blood flow. It is possible that ergot alkaloids have vasoconstrictive potential over 
vasculature in the gastrointestinal tract. As the barrier function of the gastrointestinal tract 
may become compromised, absorption of nutrients may become altered. As well as 
nutrient absorption becoming altered, the protective barrier the gastrointestinal tract 
provides may begin to break down, which could have a profound effect on the health of 
livestock.  
Gastrointestinal Tract Anatomy, Histology, and Physiology 
 The gastrointestinal (GI) tract is a multilayered barrier that plays roles in 
absorption, digestion, and protection.  It is responsible for the absorption of fluids and 
nutrients, secretion of drugs and drug metabolites, and acts as a barrier against harmful 
bacteria and toxins from the intestinal lumen (Nunes et al., 2015; Barreau & Hugot, 2014; 
Lennernas, 2013). These processes occur due to the infolding structure of the GI tract. 
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Around 90% of all absorption in the GI tract occurs in the small intestine region (Nunes 
et al., 2015). In ruminants, the small intestine extends from the abomasum to the large 
intestine and is broken up into three regions: the duodenum, jejunum, and the ileum.  
The small intestine is composed of four connected layers: the mucosa, 
submucosa, muscularis propria, and the serosa (Pereira et al., 2015; Rao & Wang, 2010) 
(Figure 2.3). The mucosa is the innermost layer and also the most complex as it is 
composed of three layers. The epithelial monolayer is the first layer and is in contact with 
the intestinal lumen (Pereira et al., 2015). This monolayer separates the intestinal lumen 
from the lamina propria. The monolayer of cells is in contact with immunological agents, 
commensal bacteria, mucus, and nutrients (Pereira et al., 2015). The second layer is the 
lamina propria and it is composed of connective tissue, capillaries, and lymph nodes. It 
absorbs digestive products. The third and final layer of the mucosa is the muscularis 
mucosae which is a thin layer of smooth muscle (Pereira et al., 2015; Abreu, 2012; Rao 
& Wang, 2010). It is at the base of crypts and contains vascular and lymphatic capillaries 
that also aid in the digestive process. 
Enterocytes and Secretory Cells 
According to Crosnier et al. (2006), unique mechanisms in the intestinal 
epithelium, such as cell proliferation, differentiation, and apoptosis, occurs in that 
particular order along the crypt-villus axis. Proliferative crypts are invaginations that 
contain intestinal epithelial stem cells and transit-amplifying cells (Pereira et al., 2015). 
Transit-amplifying cells are partially differentiated cells that divide four to five times 
before terminal differentiation (Pereira et al., 2015). Two types of cells are generated 
from this process: absorptive enterocytes and secretory cells. Enterocytes make up more 
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than 80% of all intestinal cells. The monolayer of enterocytes is highly absorptive and 
has a large absorptive area due to being composed of a large number of villi (Lennernas, 
2013). Enterocytes are columnar, highly polarized and have distinct apical and 
basolateral membranes (Nunes et al., 2015; DeSesso & Jacobson, 2001; Reitsma et al., 
2014). Secretory cells are further subdivided into goblet cells, enteroendocrine cells, and 
Paneth cells (Pereira et al., 2015). Secretory cells have roles in innate immunity through 
protein secretion, hormone secretion, and mucin secretion while enterocytes act as a 
barrier and absorb nutrients. 
Intestinal Absorption and Transport 
 Membrane transporters act as gatekeepers for cells and control influx and efflux 
of sugars, nucleotides, amino acids, organic ions, and drugs (Estudante et al., 2012; 
Hediger et al., 2004). The two major sites that affect the amount of a drug that passes into 
the systemic circulatory system after an oral dose are the liver and the intestines. There 
has been extensive research focused on the role of drug transporters in the liver (Shitara 
et al., 2006; DeGorter et al., 2009; Li et al., 2009; Faber et al., 2003) and kidneys (Shitara 
et al., 2006; van Montfoort et al., 2003; Kikuchi et al., 2010) but not as much on the role 
of influx and efflux transporters in the small and large intestines (Oswald et al, 2007).  
For orally administered drugs and nutrients to reach capillaries that lead to the 
portal vein, they must first pass through the gut wall mucosa. The closely-linked 
polarized enterocytes (Estudante et al., 2012) that make up the mucosa are sealed by tight 
junctions. Intestinal drug transporters are of increasing interest as several drug 
transporters have been identified in enterocytes that make up the gut wall mucosa. 
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Molecules may pass through gut membranes by passive diffusion or active mechanisms 
(Estudante et al., 2012). 
Factors Governing Permeability Across Intestinal Epithelium 
 The extent and rate to which a drug or nutrient is absorbed across the intestinal 
wall depends on numerous factors. They are physiochemical properties, physiological 
properties, anatomical properties, biochemical factors, and factors related to dosage form 
(Nunes et al., 2015; Agoram et al., 2001; Ungell et al., 1998). According to a study by 
Dahan et al. (2009) the fundamental events that control absorption are the permeability of 
the drug or nutrient through the GI membrane and the solubility of a drug or nutrient in 
the GI environment. Nutrients also face physical barriers, such as luminal barriers and gut 
wall barriers, which control the amount that is absorbed across the intestine. 
 The intestinal epithelium is covered with a mixture of water, mucus, and 
glycocalyx (Pereira et al., 2015). This mixture acts as a protective barrier but it is also 
permeable to nutrients and small molecules. The mucus component is a hydrogel-like 
structure that is responsible for particle clearance due to its rapid turnover time (Atuma et 
al., 2001). The structure of intestinal mucus can also increase transcellular transport of a 
compound (Ensign et al., 2012).  
 Not only does the mixture of water, mucus, and glycocalyx influence the 
absorption of nutrients but the epithelium itself does as well. The epithelium is reinforced 
by tight junctions and efflux transporters. Tight junctions keep bacteria and molecules 
larger than 200 Da out via the paracellular transport pathway (Chen et al., 2011). Tight 
junctions also work together with efflux transporters, particularly P-glycoprotein 1 (P-gp; 
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MDR1; ABCB1) and breast cancer resistant protein (BCRP; ABCG2). Efflux 
transporters push unwanted substances back into the intestinal lumen. 
Transport Pathways Across Intestinal Epithelium  
 Transport across the intestinal membrane is a complex process and involves 
several pathways in parallel and along the small intestine (Nunes et al., 2015; Balimane et 
al., 2000; Lennernӓs, 2014). Transport of drugs varies from one drug to the next 
depending on the properties of that particular drug. There are two general types of 
transport: passive transport and active transport. Passive transport and active transport 
can be further subdivided based on properties and functions (Figure 2.4). 
Passive Transport 
 Passive transport involves the movement of molecules across a concentration 
gradient without the use of energy. It is not saturable and shows a low specificity for 
structure of the molecule (Shargel & Yu, 1999). The only form of passive transport that 
requires a carrier protein or ionophore and that is a saturable process is facilitated 
diffusion. It does not need energy as it is dependent on the concentration gradient 
(Dobson & Kell, 2008). Passage of molecules from the intestinal lumen through the 
mucosa occurs mainly by two passive mechanisms: transcellular diffusion (through cells) 
and paracellular diffusion (between adjacent cells) (Nunes et al., 2015; Antunes et al., 
2013). 
Transcellular Diffusion 
 Passive transcellular transport allows compounds to cross from one side of the 
cellular membrane to the other through the lipid bilayer. Large particles and 
macromolecules typically utilize the transcellular route (Barreau & Hugot, 2014) as this 
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type of transport is not saturable and therefore not subject to inhibition. This form of 
transport is also much less sensitive to the structure of drugs (Nunes et al., 2015; Sugano 
et al., 2010). Rapidly and completely absorbed drugs are typically lipophilic and will 
distribute readily into cell membranes of the intestinal epithelium (Artursson et al., 2001). 
As the lipid bilayer is highly hydrophobic, diffusion of compounds across the cell 
membranes is limited to uncharged and desolvated compounds and depends on molecular 
size and affinity for the lipid bilayer (Nunes et al., 2015). It can be assumed that drugs 
that meet this criterion are transported almost exclusively by passive transcellular 
diffusion (Artursson et al., 2001).  
Paracellular Diffusion 
 Drugs that are slowly or incompletely passively absorbed distribute poorly into 
cell membranes and it is assumed that these drugs are transported paracellularly 
(Artursson et al., 2001). Drugs that typically follow the paracellular transport pathway are 
peptides and hydrophilic drugs, but it is not known if these drugs use paracellular routes 
exclusively (Artursson et al., 2001; Nellans, 1991). Paracellular transport allows water, 
solutes, and ions to pass through and is restricted by tight junction proteins (Antunes et 
al., 2013; Nunes et al., 2015). The surface area of tight junction proteins is 0.1% of the 
total surface area and tight junctions restrict the paracellular transport of drugs (Artursson 
et al., 2001; Furuse et al., 1993). Drug transport across the intestinal epithelium by 
paracellular transport is thought to be minimal and dependent on the size of the molecule 
attempting to utilize this pathway. Tight junction permeability is further restricted due to 
the fact that tight junctions are charge selective (Nunes et al., 2015). Compounds and 
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molecules transported by the paracellular mechanism are not exposed to lysosomes 
within the enterocyte and are not broken down (Nunes et al., 2015; Reitsma et al., 2014). 
Active Transport 
 Active transport is a form of transport that requires energy and is saturable. 
Saturation is limited by the number of protein transporters that are present (Cabrera-Pérez 
et al., 2015). Active transport requires energy as molecules are pumped against a 
concentration gradient or going “up-hill.” Various hydrophilic drugs have chemical 
structures that are similar to various nutrients that capable of being transported across the 
intestinal epithelium by active, carrier-mediated transport (Artursson et al., 2001). Active 
transport is selective and can be interfered by the presence of inhibitors (Cabrera-Pérez et 
al., 2015). 
 There are two types of active transport: primary active transport and secondary 
active transport. Primary active transporters utilize energy coming from the hydrolysis of 
ATP while secondary active transporters utilize the energy that is generated from an 
electrochemical gradient from a primary transporter (Cabrera-Pérez et al., 2015).  There 
is no direct ATP coupling occurring in secondary active transport. Secondary active 
transport uses cotransporters such as symporters or anitporters. Symporters transport 
molecules in the same direction while antiporters transport molecules in opposite 
directions. 
Endocytosis  
 Endocytosis (also known as vesicle-mediated transport, is a form of active 
transport involving the cell membrane in which materials are taken into the cell via cell 
membrane invaginations. The cell membrane forms a fold around the desired material, 
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enclosing the material, then fuses again, forming a vesicle (Cabrera-Pérez et al., 2015). 
This vesicle transports the engulfed material across the membrane to the inside of the cell 
(Cabrera-Pérez et al., 2015). Endocytosis can further be divided into two subtypes: 
phagocytosis and pinocytosis. Phagocytosis allows for an entire cell to be engulfed 
whereas pinocytosis engulfs external fluids. It is possible that endocytosis plays a minor 
role in drug and nutrient absorption, sans protein based molecules (Cabrera-Pérez et al., 
2015). 
Influx and Efflux Facilitated Transport  
There are studies linking the absorption of ergot alkaloids across pre-gastric 
tissues, but there is a paucity of information concerning the absorption and transport of 
ergot alkaloids across the small intestine. Influx and efflux transport systems belong to 
either the ATP-binding cassette (ABC) transporter family or the solute carrier (SLC) 
transporter family (Maubon et al., 2007; Petzinger & Geyer, 2006; Ware, 2006) (Figure 
2.5). Both transporter families play essential roles concerning transport of compounds 
across cell monolayers. Therefore, transporter proteins may play an important role in the 
drug pharmacokinetic profiles by controlling drug disposition. 
ATP- Binding Cassette Transporters 
 ATP-binding cassette (ABC) proteins are present in almost all living organisms 
ranging from prokaryotes to mammalian species (Szakács et al., 2008). They are active 
transporters and require energy in the form of ATP. ABC transporters restrict the fraction 
of a drug absorbed by pumping the compound out of the cells into the lumen (Chan et al., 
2004; Varma et al., 2010). There are three main functional categories of ABC 
transporters: importers, exporters (effluxers), and those involved in DNA repair and 
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translation. In prokaryotes, they exist as importers. In eukaryotes, ABC transporters 
function as exporters or effluxers, pumping out toxins, drugs, or possibly nutrients. The 
final subgroup does not act as a transporter, but is involved in DNA repair and translation 
processes (Davidson et al., 2008).  
ABC proteins involved in transport are bound to the membrane and built from a 
combination of membrane-spanning regions and cytoplasmic ATP binding domains 
(Szakács et al., 2008). All ABC transporters contain four core domains: two trans- 
membrane (T) domains and two cytosolic (A) domains (Dean et al., 2001). The T 
domains switch between inward and outward facing positions which are powered by ATP 
hydrolysis (Dean et al., 2001). ATP binds to the A subunits and is hydrolyzed. Transport 
is linked to the ATPase activity of ABC proteins (Senior et al., 2004). ABC subfamilies 
involved in intestinal transport are the ABCB subfamily and the ABCC subfamily, with 
P-glycoprotein and breast cancer resistance protein being two of the primary members. 
P-glycoprotein 
 P-glycoprotein, also known as ABCB1 and P-gp, was first isolated from cancer 
cells and plays an important role in expelling drugs out of the cell which has led to 
multidrug resistance (Liu & Liu, 2013). P-gp is ATP-dependent and has a broad substrate 
specificity. In humans, P-gp is encoded by two genes, MDR1 and MDR3, and in rodents 
it is encoded by MDR1a, MDR1b, and MDR2 (Kunta & Sinko, 2004). It is located at 
brush border membranes of enterocytes and functions as an efflux pump before drugs and 
toxins can access the portal circulation. Various anticancer drugs, such as vincristine, 
immunosuppressants, steroids, verapamil, and digoxin act as substrates for P-gp (Adachi 
et al., 2001). It has been suggested that P-gp and cytochrome P450 3A4 (CYP3A4) 
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cooperate in the intestinal absorption of drugs. CYP3A4 is an enzyme found in intestines 
and liver and oxidizes small foreign organic molecules such as drugs and toxins for 
removal from the body. 
Breast Cancer Resistance Protein 
 Breast cancer resistant protein, also known as BCRP or ABCG2, is a half-
transporter that is expressed in breast tissue, the ovaries, colon, liver, and small intestine 
(Colabufo et al., 2009; Allikmets et al., 1998; Maliepaard et al., 2001). BCRP is located 
at the apical part of the plasma membrane in epithelia (Liu & Liu, 2013). It is thought 
that BCRP plays a protective role in the GI tract as it prevents the absorption of toxic 
substances. BCRP effluxes similar substrates as P-gp which suggests that BCRP acts as a 
half-transporter compared to P-gp regarding drug and nutrient absorption (Taguchi et al., 
1997). This could be explained by the fact that BCRP only has six transmembrane 
domains while P-gp has twelve.  
Solute Carrier Transporters  
The solute carrier (SLC) group of transporters includes over 300 members of 
transporters that are organized in 52 families (Hediger et al., 2004). Most SLC 
transporters are located within the cell membrane and can transport a diverse array 
molecules and ions. Transport proteins within the SLC group are either facilitative 
transporters or secondary active transporters. For instance, oligopeptide transporter 1 
[PepT1] and organic ion transporter polypeptide A [OATPA] rely on ion gradients (e.g. 
H+ and Na+ gradients) that are created by primary active carriers (Varma et al., 2010). 
The SLC family does not contain transport proteins that are classified as primary active 
transporters, ion channels, or aquaporins. SLC transporters enhance the absorption of 
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drugs and nutrients into cells that can result in increased plasma levels of drugs and 
nutrients (Liang et al., 1995). 
Peptide Transporter 1 
 Peptide transporter 1, also known as PepT1 or SLC15A1, is a proton-coupled 
transport protein that is encoded by the SLC15A1 gene in humans (Liang et al., 1995). 
PepT1 acts as a cotransporter (Adibi, 1997) and is functional in the intestines. In the 
intestines, PepT1 is located in the brush border membrane of the epithelium. It plays an 
important role in uptake of nutrients, specifically dipeptides and tripeptides, across the 
apical membrane (Adibi, 1997). PepT1 is of pharmacological interest because it accepts 
numerous drugs and prodrugs as substrates (Brandsch, 2013) and due to overexpression 
in malignant cancer cells (Nakanishi et al., 2000; Gonzalez et al., 1998) it is an important 
target for drug design to improve bioavailability. Prodrugs are drugs that are metabolized 
to a metabolically active form once administered. Prodrugs are grouped into two 
categories: those that are designed to resemble peptides for uptake via di and tri-peptide 
transporters and those that are developed to improve solubility or lipophicility (Brodin et 
al., 2002). Certain β-lactam antibiotics fall into the second category of prodrugs 
(Bretschneider et al., 1999). In recent years, it has been established that PepT1 is largely 
involved in intestinal absorption of β-lactam antibiotics (Bretschneider et al., 1999; 
Sugawara et al., 2003; Terada et al., 1997). β-lactam antibiotics possess similar features 
common with dipeptides, oncluding a terminal carboxylic acid group, an α-amino group, 
and a peptide bond (Dantzig et al., 1988).  
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Organic Anion-Transporting Proteins 
 Organic anion-transporting proteins (OATPs) are transport proteins that allow the 
transport of organic anions across the cell membrane. They act as gatekeepers and are 
present in the lipid bilayer of the cellular membrane of the brain, eyes, smooth muscles, 
and basolateral membrane of proximal tubular cells of the kidneys. They belong to the 
SLC family and are more specifically members of the solute carrier organic anion 
(SLCO) gene subfamily (Kullak-Ublick et al., 1997). In humans, OATP A is encoded by 
the SLCO1A2 gene (Kullak-Ublick et al., 1997). This transporter is found in almost every 
tissue and plays a role in the transport of drugs across the cell membrane. However, a 
study by Meier et al. (2007) found no detectable levels of SLCO1A2 mRNA in the 
duodenum of humans. Substrates of OATP-A include bile acids, thyroid hormones, and 
steroid hormones (Kullak-Ublick et al., 1995; Bossuyt et al., 1996; Fujiwara et al., 2001). 
Caco-2 Cells as an Intestinal Model 
Importance of Cell Models 
 It is important to evaluate molecule permeability in the early stages of drug 
development and nutrient profiling because it allows for selection of the best molecule 
for the targeted transporter (Cabera-Pérez et al., 2015). Cell-based models of different 
barriers have been useful as they are relatively simple, have a high-throughput, are 
predictable in behavior and abilities, and are cost effective (Cabrera-Pérez et al., 2015) 
The main limitation of using a cell model is the variability in results (Cabrera-Pérez et al., 
2015). Results vary based on temperature, protocol, cell line, passage number, culture 
medium, and the manipulator, making it very difficult to compare published data 
(Cabrera-Pérez et al., 2015). However, suitable permeability assays can be developed if 
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the protocol is confirmed by a standardized procedure and if high-permeability internal 
standards, markers, and reference compounds are used (Volpe, 2010). 
Caco-2 Cell Background  
Because the oral route is how most nutrients are obtained, the intestinal barrier 
has received extensive attention. The Caco-2 cell line is a heterogeneous human epithelial 
cell line that was derived from a colorectal carcinoma by the Sloan-Kettering Institute for 
Cancer Research (Fogh & Trempe, 1975). Caco-2 cells are considered to be the “gold 
standard” cell model for predicting intestinal absorption (Pereira et al., 2015; Hidalgo, 
2001). Caco-2 cells were found to simulate the intestinal barrier and are used as an in 
vitro model (Artursson et al., 2001). In a study conducted by Hilgers et al. (1990) it was 
found that after 21 days, Caco-2 cells seeded into 3-μm-pore membrane inserts at 60,000 
cells/cm2 showed confluent monolayers with well-defined tight junctions, transporters, 
and enzymes. While Caco-2 cells are derived from a large intestinal carcinoma, when 
cultured under certain conditions, the cells differentiate and become polarized, 
resembling enterocytes that line the small intestine (Pinto et al., 1983; Hidalgo et al., 
1989).  
Caco-2 cells are not used as individual cells but rather are typically grown as 
monolayers on a membrane-containing insert (Figure 2.6). When cultured this way, cells 
will differentiate and form a polarized epithelial monolayer, providing a physical and 
biochemical barrier towards small molecules and ions (Hidalgo et al., 1989; Artursson, 
1990). The insert system is composed of 10μM thick membrane with different pore sizes. 
When epithelial cells are seeded onto the membrane, this creates apical and basolateral 
compartments which are similar to the epithelia lining the intestinal lumen (Pereira et al., 
25 
 
2015). The Caco-2 monolayer on a membrane insert is widely used in the pharmaceutical 
industry as an in vitro model to predict the absorption of nutrients and drugs and has its 
advantages and limitations (Shapell and Smith, 2005; Mulac et al., 2012; Watanabe et al., 
2003; Bravo et al., 2003; Artursson et al., 2001). 
Validation of the Caco-2 Cell Line 
 The primary goal of establishing a Caco-2 monolayer is to create an in vitro 
model that mimics the intestinal barrier to study and profile drugs, toxins, and nutrients 
and how they are absorbed though said barrier. Three characteristics allow the model to 
be validated: these characteristics are monolayer integrity, differentiation, and 
functionality. Model integrity can be studied by measuring transepithelial electrical 
resistance (TEER). TEER measurements measure absolute values of resistance per unit of 
area and are measured in units of ohms (Pereira et al., 2015). Tight junctions modulate 
the transport of molecules by paracellular transport and the tighter the tight junctions, the 
higher the TEER measurements (Pereira et al., 2015). In addition to TEER, small 
molecules such as mannitol, Lucifer yellow, and dextran can also be used as evidence of 
membrane integrity (Pereira et al., 2015).  
Transport and Possible Metabolic Routes of Alkaloids in Ruminants   
As mentioned previously, of the ergopeptine alkaloids produced by tall fescue, 
ergovaline is produced in the largest proportions by the endophyte and has been 
implicated as the primary toxin associated with tall fescue toxicosis (Bush et al., 1997; 
Paterson et al., 1995; Strickland et al., 1993). Yates et al. (1985) determined that 
ergovaline was the most prominent ergopeptine alkaloid in samples from KY-31 pastures. 
Based on its concentration in the plant, ergovaline was presumed to be the toxin 
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responsible for causing fescue toxicosis. However, it has been suggested that lysergic 
acid is involved in disease progression as well. Stuedemann et al. (1998) used urinary and 
biliary alkaloid excretion patterns and ELISA quantification to suggest that lysergic acid 
amides and biotransformed ergopeptine alkaloids were rapidly absorbed. This suggests 
that another ergot alkaloid may be responsible for fescue toxicity. Hill et al. (2001) 
supported these findings with studies that were conducted to compare alkaloid transport 
in ovine omasal, reticular, and ruminal tissues and to determine whether transport was 
active or passive. The aforementioned tissues were removed and placed in parabiotic 
chambers with equimolar concentrations of lysergic acid, lysergol, ergonovine, 
ergotamine, and ergocryptine with Kreb’s Ringer phosphate (KRP) solution on the 
mucosal side of the tissues. Samples were taken from KRP on the serosal side during 
allotted times during the 240 min incubation period. Ruminal tissue had greater ergot 
alkaloid transport potential than omasal tissue and reticular tissue due to a larger surface 
area. Transport of alkaloids seemed to be an active process, with lysergic acid and 
lysergol having the greatest transport potential. Ergopeptine alkaloids appeared to pass 
across omasal tissues in larger quantities than in ruminal tissues but this transport was 
minimal when compared to lysergic acid and lysergol transport. 
Hill et al. (2001) reported that lysergic acid crossed ruminal epithelium at greater 
rates than other alkaloids tested and suggested that lysergic acid may be responsible for 
fescue toxicosis. However, not all alkaloids present in E+ tall fescue, including 
ergovaline, were tested for in determination of transport across ruminal epithelium. Durix 
et al. (1999) used 4 lactating goats to develop an HPLC assay to quantify ergovaline in 
milk after intravenous injection of ergovaline into the right jugular vein.  It was suggested 
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that the physiological response to ergovaline did not require metabolism by the 
gastrointestinal tract after administration of purified ergovaline resulted in physiological 
effects that were similar to ergovaline toxicity. This implies that metabolism by 
gastrointestinal microbes or the liver may not be required for ergovaline’s immediate 
physiological effects. 
At present, the site(s) and mechanism(s) of ergot alkaloid absorption have not 
been fully described.  In two experiments conducted by Westendorf et al. (1993), 
different combinations of the alkaloids N-formyl and N-acetyl loline were incubated in 
ruminal fluid for three timepoints (0, 24, and 48 hr). Disappearance of N-formyl and N-
acetyl loline increased over time. Significant amounts of both alkaloids were metabolized 
and converted to loline.  The second experiment was comprised of abomasally cannulated 
sheep that were given doses of 945 mg and 2346 mg of ergovaline and ergovalinine per 
day. Up to 50-60% of the alkaloids in the abomasal contents were recovered as compared 
to the 5% recovered in fecal material. From the in vitro experiment, it can be concluded 
that alkaloids in general may be degraded by ruminal microbes. However, in the in vivo 
study, recoveries of pyrrolisidine alkaloids in abomasal fluids and feces were lower than 
those of the ergot alkaloids. In support of these findings, Schumann et al. (2009) 
conducted a study in order to examine the effects of ergot contaminated concentrate at 
differing levels of feed intake on ergot alkaloid metabolism and carry over into milk. The 
findings of this study were similar to the findings of Westendorf et al. (1993). It was 
determined that 67% of ergot alkaloids examined reached the duodenum. It was also 
found that only ~24% of alkaloids were excreted with fecal material. In both studies, 
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there is a sharp drop-off of alkaloid recovery from abomasal/ duodenal contents and fecal 
material, suggesting that some alkaloid absorption could occur in the small intestine. 
Ergot Alkaloid Transport Across the Small Intestine 
Eckert et al. (1978) found that many toxicants are absorbed via passive transport 
across the gastrointestinal epithelia and that absorption of ergot alkaloid compounds 
appears to be limited to the small intestine in nonruminants. Savary et al. (1991) 
published one of the few studies linking ergovaline absorption across the digestive tract 
in ruminant species. Ergovaline and its diastereoisomer ergovalinine were found in serum 
from steers that were grazing on endophyte-infected fescue. However, quantitative 
assessment was not possible as serum levels of ergovaline and ergovalinine were close to 
the analytical limit of detection when using high-pressure liquid chromatography 
(HPLC). Shapell and Smith (2005) used Caco-2 cells as a model of human intestinal cells 
to demonstrate the movement of a 60:40 ratio of ergovaline/ergovalinine isomers. Isomer 
movement was assessed using HPLC. It was found that ergovaline and ergovalinine 
crossed intestinal cells at similar rates. It was suggested that either isomer, or a 
combination, could be involved in the pathogenesis of fescue toxicosis. However, no 
other ergot alkaloids were tested in this study. 
Summary and Statement of Objectives 
The objectives of this thesis are to determine if  ergotamine, ergovaline, and 
lysergic acid utilize peptide transporter 1 in a Caco-2 cell monolayer small intestine 
model, and to identify serotonin receptors in ruminal and mesenteric vasculature that 
could be affected by ergot alkaloid absorption. 
  
29 
 
Figure 2.1 Alkaloids present in endophyte positive tall fescue; A: pyrrolopyrazine, 
peramine, B: pyrrolizidine, general loline structure, C: ergoline ring structure, D: clavine 
structure, E: lysergic acid amide structure, F: peptide alkaloid structure 
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Figure 2.2 Vasoconstriction causing catecholamines: A: serotonin (5-HT), B: 
epinephrine (EP), C: norepinephrine (NE) 
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Figure 2.3 Histology of the small intestine. The small intestine is composed of four 
layers: A: serosa (outermost layer), B: muscularis propria, C. submucosa, and D. mucosa 
(innermost layer). 
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Figure 2.4 General forms of A: passive transport and B: active transport 
 
 
Figure 2.5 ATP-binding cassette (PepT1and OATP A) and solute carrier transporter (P-
gp and BCRP) cellular locations in intestinal epithelial cells. 
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Figure 2.6 Cell membrane insert dividing growth wells into apical and basal 
compartments. 
White arrows represent potential cellular growth on a membrane insert. 
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CHAPTER THREE: PHARMACOLOGIC ASSESSMENT OF BOVINE 
RUMINAL AND MESENTERIC VASCULAR SEROTONIN RECEPTOR 
POPULATIONS 
Introduction 
Epichlöe coenophiala is an endophyte symbiotically related with tall fescue grass 
(Lolium arundinaceum). E. coenophiala produces numerous ergot alkaloids (EA) which 
have been identified as causative agents of vasoconstriction associated with fescue 
toxicosis. Various studies have reported that EA induce vasoconstriction in bovine 
uterine and umbilical arteries (Dyer, 1993), right ruminal artery and vein (Foote et al., 
2011), mesenteric artery and vein (Egert et al., 2014), and lateral saphenous vein (Klotz 
et al., 2008; Klotz et al., 2010). Ergot alkaloids have structural similarities with biogenic 
amines, such as serotonin (5-hydroxytryptamine, 5-HT), and cause vasoconstriction by 
binding to receptors (Dyer, 1993; Berde, 1980), possibly causing decreased blood flow 
observed in gastrointestinal vasculature (Rhodes et al., 1991; Foote et al., 2011). 
Foote et al. (2011) found that ergot alkaloids could play a role in vasoconstriction 
of the bovine right ruminal artery and vein, possibly reducing blood flow to or from the 
rumen and resulting in decreased absorption rates of nutrients and fermentation products. 
Ergot alkaloid-induced vasoconstriction was not only seen in ruminal vasculature but also 
in mesenteric vasculature. Egert et al. (2014) demonstrated that various ergot alkaloids 
were vasoactive in bovine mesenteric vasculature. Further, steers with prior exposure to 
endophyte-infected tall fescue had a diminished response to many ergot alkaloids and 5-
HT in the mesenteric vasculature. Because there are a number of different serotonin 
receptor subtypes (Hoyer et al., 1994), it is necessary to assess the receptor populations 
available for possible ergot alkaloid interaction. Therefore, the objective of this study was 
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to pharmacologically determine which 5-HT receptors are involved in contractility of 
bovine gut vasculature using agonists selective for 5-HT1D, 5-HT1B, 5-HT2A, 5-HT2B, 5-
HT4, and 5-HT7 receptors. 
Materials and Methods 
No live animals were involved in this study, thus approval from the University of 
Kentucky Animal Care and Use Committee was not required. 
Animals and Tissue Collection 
Blood vessels were collected from the carcasses of twenty-four mixed breed and 
gender cattle between ten and thirty months of age (542 ± 23 kg) that were slaughtered at 
the University of Kentucky Meats Lab or Hi-View Meats (Sadieville, KY). As previously 
described by Klotz and Barnes (2014), the gastrointestinal tract was removed and the 
ileocecal fold and ileal flange were identified as landmarks in order to remove multiple 
branches of common mesenteric artery (MA) and vein (MV) segments. The ventral 
coronary and caudal grooves were identified as landmarks to remove segments of the 
right ruminal artery (RA) and vein (RV) as previously described  (Klotz et al.,2011). 
Vessel segments of 2 – 3 cm were immersed and transported in oxygenated Krebs-
Henseleit buffer (95% O2/ 5% CO2; pH = 7.4; 11.1 mM D-glucose; 1.2 mM MgSO4; 1.2 
mM KH2PO4; 4.7 mM KCl; 118.1 mM NaCl; 3.4 mM CaCl2; 24.9 mM NaHCO3; Sigma 
Chemical Co., St. Louis, MO, USA). The MA, MV, RA, and RV were stored on ice until 
they were separated and cleaned of surrounding fat and fascia. Vessels were sliced into 
approximately 2-mm segments and viewed under a dissection microscope (Stemi 2000-C, 
Carl Zeiss Inc., Oberkochen, Germany) at 12.5x magnification to check for vessel 
abnormalities (structural damage and branches) and to assess vascular dimensions. Cross-
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sections with structural damage were replaced with undamaged segments. Because MV 
and RV are pliant, vascular dimensions were only recorded for MA and RA cross 
sections using Axiovision (version 20, Carl Zeiss Inc.). 
Standard Preparations 
All receptor agonists were obtained from Tocris Bioscience (Minneapolis, MN, 
USA). Stock solutions of the agonists TCB-2 (TCB-2; Cat. No. 2592), CP 93129 
dihydrochloride (CP 93129; Cat. No. 1032), LP 44 (LP 44; Cat. No. 2534), BIMU-8 
(BIMU-8; Cat. No. 4374), BW 723C86 hydrochloride (BW 723C86; Cat. No. 1059), and 
L-694, 247 (L-694, 247; Cat. No. 0781) (Table 3.1) were diluted to corresponding 
concentrations for final working concentrations in tissue wells of 1 x 10-11 to 1 x 10-4 M 
for LP 44 and 5 x 10-9 to 1 x 10-4 M for all other agonists. LP 44, BW, L-694, TCB-2, and 
BIMU-8 were prepared in dimethylsulfoxide (DMSO) (472301; Sigma Chemical Co.). 
CP 93129 was prepared in H2O. Eight standard additions of LP 44 were prepared based 
on available stock of LP 44 (1x10-11, 1x10-10, 1x10-9, 1x10-8, 1x10-7, 1x10-6, 1x10-5, and 
1x10-4M). For all other agonists, there were a total of ten standard additions (5x10-9, 
1x10-8, 5x10-8, 1x10-7, 5x10-7, 1x10-6, 5x10-6, 1x10-5, 5x10-4, and 1x10-4M). All additions 
were added to tissue chambers in increasing order of concentration in volumes that did 
not exceed 0.5% of the total buffer. 
Myograph Protocol  
Mesenteric and ruminal artery and vein cross-sections were mounted onto luminal 
supports in individual wells of a multimyograph (DMT 610M, Danish Myo Technology, 
Atlanta, GA) containing 5 mL Krebs-Henseleit buffer subject to constant gassing (95% 
O2/ 5% CO2; pH =7.4; 37°C). The incubation buffer was the same composition as the 
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transport buffer plus 3 x 10-5 M desipramine (D3900; Sigma Chemical Co.) to inactivate 
neuronal catecholamine uptake and 1 x 10-6 M propranolol (P0844; Sigma Chemical Co.) 
to block β-adrenergic receptors. Vessels were allowed to equilibrate under the above 
conditions for 90 min with buffer changes occurring every 15 min to allow a vessel to 
equilibrate at a resting tension of approximately 1 g. Experimental tissues were exposed 
to a reference addition of 120 mM KCl (Sigma Chemical, Co.) for 15 min to confirm 
tissue responsiveness and viability. Vessels were rinsed with new incubation buffer every 
15 min until approximately 1 g of tension was reached. Once vessels had returned to 
resting tension, standard additions were added for contractile response experiments. 
Additions were added in 15-min cycles. Each cycle consisted of a 9-min incubation 
period, 2 2.5-min buffer washes, a final buffer replacement, and 1-min recovery period 
before the next standard addition. Vessels were again exposed to 120 mM KCl once the 
experiment was completed to verify vessel viability for the entire experiment. 
Isometric contractions in mesenteric and ruminal vessels to KCl, LP 44, CP 
93129, BW 723C86, L-694, 247, TCB-2, and BIMU-8 were digitized and recorded in 
grams of tension using PowerLab16/35 and Chart software (version 7.3, ADInstruments, 
Colorado Springs, CO). Baseline tension was recorded before addition of 120 mM KCl. 
For all contractile response data, the maximum tension (measured in g) during the 9-min 
incubation was recorded as the contractile response and then corrected for baseline 
tension. Due to variation between animals and tissues, contractile response data was 
normalized as a percentage of the maximum grams of tension induced by the reference 
addition of KCl to compensate for differences in vessel responsiveness. Vessel contractile 
response data are reported as the percentage mean contractile response ± SEM of the 
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maximum contractile response produced by the 120 mM KCl reference addition. 
Sigmoidal concentration response curves of ruminal and mesenteric vasculature to 5-HT 
agonists were calculated and plotted using nonlinear regression with fixed slope 
(GraphPad Prism 7, GraphPad Software Inc., La Jolla, CA). Data were plotted and 
calculated using a 3-parameter equation: 
𝑦 = bottom + (top−bottom)[1+10(logEC50−x)] , 
where y represents contractile response, x represents agonist concentration, top and 
bottom are the percentage of 120 mM KCl maximum contractile response at the plateaus, 
and EC50 is the molar concentration of the agonist producing 50% of the maximum 
response of KCl.  
Statistical Analysis 
 All data were analyzed using the MIXED model of SAS (SAS 9.3, SAS Inst. Inc., 
Cary, NC). Contractile response and EC50 data for each agonist were analyzed as a 
completely randomized design for effect of agonist concentration. Mesenteric and 
ruminal arteries and veins were the experimental units. A vessel x agonist concentration 
interaction was analyzed with vessel and agonist concentration being the main effects. 
Mean separation was conducted for data if the probability of a greater F-statistic in the 
ANOVA was significant for the effect of agonist concentration. Individual mean 
differences were evaluated by using the LSD feature of SAS. Data were analyzed for 
deviations from normality and homogeneity. Results are considered significant if 
probabilities are P < 0.05, unless reported otherwise. 
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Results and Discussion 
Exploration of the Presence of 5-HT2A Receptors: Responses to TCB-2 
To our knowledge, this is the first study to profile the 5-HT receptor subtypes 
present in bovine ruminal and mesenteric vasculature. Because there are numerous 5-HT 
receptor subtypes located throughout the body, the biological responses to 5-HT are 
complex and not fully characterized. Serotonin can act as a vasodilator or vasoconstrictor 
depending on the animal species, blood vessel type, or status of the endothelial cell layer 
(Ni and Watts, 2006). The 5-HT2A subtype is the primary receptor involved in 
vasoconstrictive responses. The current study found that there was a significant 
contractile response for mesenteric and ruminal vasculature to the 5-HT2A agonist TCB-2 
(P < 0.05) (Figure 3.1). Klotz et al. (2013) had previously identified the presence of 5-
HT2A receptors in bovine lateral saphenous veins using the antagonist ketanserin. The 
onset of the contractile response was observed at the addition of 5 x 10-5 M TCB-2 for the 
MA, MV, and RV (P < 0.05) whereas the RA reached a maximal contractile response 
when exposed to a lower concentration, 5 x 10-6 M TCB-2 (P < 0.05).  
For EC50 values, only data regarding 5-HT2A was considered as all other 
experimental agonists failed to produce a positive sigmoidal contractile response. 
Because the units of expression for EC50 values are logarithmic, the larger the EC50 value, 
the lower the TCB-2 concentration needed to achieve 50% of total response and the more 
sensitive a vessel is to TCB-2. Thus, when comparing EC50 values of vessels exposed to 
TCB-2 (Table 3.2), the EC50 value of MA was higher than that of MV (P = 0.0047) and 
RV (P = 0.0025) but did not differ from RA (P = 0.266). Ruminal arteries also had higher 
EC50 values than MV (P = 0.0004) and RV (P = 0.0002). While MV and RV were 
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different from MA and RA, they did not differ from each other (P = 0.7018).  As RV and 
MV had lower EC50 values than MA and RA, it could be suggested that TCB-2 reached 
50% of the maximum contractile response at a lower concentration, suggesting that RV 
and MV are more sensitive to TCB-2 than MA and RA. Egert et al. (2014) reported 
similar findings when exposing mesenteric vasculature to 5-HT as MA was found to be 
less sensitive to 5-HT exposure than MV.  
A significant vessel type x concentration interaction was observed for vessels 
exposed to TCB-2 (P = 0.0005; Figure 3.1). This indicates that the contractile response 
seen with TCB-2 depends on both the concentration of the agonist the vessel is exposed 
to and the type of blood vessel being used. Mesenteric arteries and RA exposed to TCB-2 
differ from RV and MV, exhibiting a larger contractile response, which is supported by 
the lower EC50 values associated with the MA and RA responses. This evidence supports 
the idea that MA and RA may have a larger amount of functional 5-HT2A receptors 
present than RV and MA. This understanding is similar to the findings of Egert et al. 
(2014), where maximal response to 5-HT appeared greater in the MA than the MV (no 
direct comparison across vessel type was conducted in this study).  
Previous myograph experiments using bovine vasculature have also shown varied 
sensitivity in response to agonist treatments. Larger contractile responses in arteries may 
be explained by the differential expression of the 5-HT2A receptor. Using rats, Kato et al. 
(1999) demonstrated that the expression of 5-HT2A receptors is significantly increased in 
the aorta compared to the vena cava. Watts (2002) also found that 5-HT2A receptors are 
the primary contractile receptor in mesenteric arteries of hypertensive rats. These findings 
indicate that there may be a larger quantity of 5-HT2A receptors in arteries than in veins. 
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Regarding the larger responses seen in ruminal vasculature as compared to mesenteric 
vasculature, differences could be due to the type of blood vessel (e.g. ruminal vessels v. 
mesenteric vessels) and a corresponding difference in 5-HT2A receptor population 
numbers. 
Vascular Responses to CP 93129, LP 44, and BIMU-8 
Ruminal and mesenteric vessels exposed to CP 93129, LP 44, and BIMU-8 did 
not exhibit contractile responses (P > 0.05) (Figure 3.2, 3.3, and 3.4). These results 
indicate that the 5-HT receptor subtypes 5-HT1B, 1D, and 5-HT4 are not present or do not 
play a role in EA-induced vasoconstriction in bovine mesenteric or ruminal vessels. It is 
possible that these receptors are present but not in concentrations high enough to be 
detected by the bioassays used in the current, or they may be present, but not functional. 
For example, Banes and Watts (2003) showed that the 5-HT1B agonist CP 93129 failed to 
cause a contraction in the aorta of rats. However, molecular expression of 5-HT1B 
receptors was demonstrated in rats, indicating that although these receptors were present, 
they were not functional or involved in aortic contractions.  
There was not a vessel x concentration interaction for vessels exposed to CP 
93129 (P = 1.0; Figure 3.2), LP 44 (P = 1.0; Figure 3.3), or BIMU-8 (P = 0.99; Figure 
3.4). However, these vessels did exhibit significant responses based on both vessel type 
and concentration of agonist. Vessels exposed to LP 44 exhibited a vessel effect (P < 
0.0001) and an agonist concentration effect (P = 0.014). Mesenteric artery and RA 
responses were not different, but relaxed less than both MV and RV. Vessels also 
responded differentially to BIMU-8 exposure (P < 0.0001) as well as responding to 
agonist concentration (P < 0.0001). Similar to vessels exposed to LP 44, MA and RA did 
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not exhibit differing responses from each other but relaxed less than both RV and MV. 
Vessels exposed to CP 93129 exhibited a vessel effect (P < 0.0001) and an agonist 
concentration main effect (P = 0.0002). MA, MV, RA, and RV are all significantly 
different from one another (P < 0.0001). For both CP 93129 and BIMU-8, MA relaxed 
less than MV and RA relaxed less than RV. In vessels exposed to CP 93129, MA had a 
stronger response than RV and RA had a stronger response than MV. This finding and 
the fact that MA and RA relaxed less in the presence of an agonist than MV and RV, 
indicate that the location from which the vessel came from (mesenteric v. ruminal) may 
not be as important as the type of vessel (artery v. vein).  
The 5-hydroxytryptamine 4 (5-HT4) receptor is coupled to adenylate cyclase and 
is distributed throughout the central nervous system and peripheral tissues, specifically in 
those tissues and organs that contain smooth muscle, such as the bladder and the 
alimentary tract. As mentioned previously, it was found in this experiment that 5-HT4 did 
not elicit a constrictive or relaxation response to the agonist BIMU-8 in ruminal or 
mesenteric vessels. 5-HT4 receptors have previously been found to induce endothelium-
independent relaxation of bovine mesenteric lymphatics (Miyhara et al., 1994). However, 
little information is available about the location of 5-HT4 receptors in core body 
vasculature. Ullmer et al. (1995) demonstrated the diversity of receptor subtypes 
expressed in various blood vessels. Reverse transcription-PCR was used to distinguish 
mRNAs for G protein-coupled 5-HT receptors expressed in rat and pig blood vessels. 
Most blood vessels expressed mRNA receptors for 5-HT1D, 5-HT2A, 5-HT2B, 5-HT4, and 
5-HT7 mRNA although they were expressed at differing levels.  Similar analogous RT-
PCR assays were performed using smooth muscle and endothelial cells from human 
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pulmonary artery, aorta, coronary artery, and umbilical vein. Of the known G protein-
coupled 5-HT receptors, only five were found to be expressed in the various blood 
vessels tested. Endothelial cells were found to express receptor mRNA for 5-HT1D, 5-
HT2B, and 5-HT4 whereas smooth muscle cells expressed 5-HT1D, 5-HT2A, and 5-HT7. 
This could explain why no response was seen in vessels exposed to BIMU-8 in our study. 
5-HT4 may be present in endothelial cells but absent in smooth muscle cells, meaning 
that contraction of the vessel cannot occur via direct acting vasoconstrictors. Ontsouka et 
al. (2014) compared the levels of mRNA and 5-HT4 receptor binding sites in smooth 
muscle layers from the GI tract of dairy cows using real-time PCR to verify if mRNA and 
protein expression were correlated. It was found that mRNA levels of the 5-HT4 receptor 
were affected by location along the GI tract. Levels in the external loop of the spiral 
colon and ileum were greater than those in the proximal loop of the ascending colon 
(mesenteric blood vessels utilized in the current study were collected from mesentery 
supporting the ileum). However, these levels of mRNA were similar to levels of receptors 
in the fundus abomasa, pylorus, and cecum. It could be concluded from this study that 
mRNA and 5-HT4 receptor binding sites were present in the smooth muscle layer of the 
entire GI tract but that they were not correlated with each other. Although Ontsouka et al. 
(2014) studied receptors in smooth muscle rather than blood vessels, the findings were 
similar to that of Ullmer et al. (1995) and suggest that 5-HT receptors may be present 
within a tissue but may not play an active role or a role that has yet to be identified. 
Vascular Responses to BW 723C86 and L-694, 247 
When exposed to the agonists BW 723C86 or L-694, 247, ruminal and mesenteric 
vasculature did not show a contractile response (P > 0.05). However, MV relaxed (P < 
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0.05) (Figures 3.5 and 3.6). This indicates that 5-HT1D and 5-HT2B receptors may be 
present in MV and contribute to vasorelaxation. A significant vessel x concentration 
interaction was observed (P = 0.0012) in vessels exposed to L-694, 247, indicating that 
the vasorelaxation response seen depends on the concentration of the agonist the vessel is 
exposed to and the type of vessel being used. Ruminal arteries and across all 
concentrations of agonist additions.  The response of MV differs from RV for the 5x10-8 
M addition onward, and is different from the RA from 1x10-8 M onwards.  
There was not a vessel x concentration interaction for vessels exposed to BW 
723C86 (P = 0.15; Figure 3.5). Vessels did, however, exhibit significant responses based 
on both vessel type (P < 0.0001) and concentration of agonist (P = 0.0013). Similar to 
vessels exposed to CP 93129, MA had a stronger response than RV and RA had a 
stronger response than MV. This indicates that the type of vessel does have an effect on 
the type and intensity of the response seen. 
The existence of 5-HT2B receptors has been reported to cause endothelium-
dependent vasorelaxation in rabbit and rat jugular vein and the porcine vena cava and 
pulmonary artery (Watts and Cohen, 1999). The existence of 5-HT7 has also been 
demonstrated in the femoral vein and pulmonary arteries of rabbits (Martin and Wilson, 
1995; Morecroft and MacLean, 1998) and in the coronary and cerebral arteries of dogs 
(Cushing et al., 1996; Terrón, 1996; Terrón and Falcón-Neri, 1999). Although Ullmer et 
al. (1995) and Bhalla et al. (2002) used RT-PCR to identify mRNA for 5-HT2B and 5-HT7 
in porcine pulmonary arteries, the presence of mRNA is not indicative of whether the 
receptor in functional or active in producing a response, as noted previously. Jähnichen et 
al. (2005) further characterized the vasorelaxative responses in pulmonary arteries 
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precontracted to prostaglandin F2α in weaned pigs. By using the 5-HT2B receptor agonist 
BW 723C86, the selective 5-HT2C receptor antagonist SB 242084, and the 5-HT2B/2C 
agonist SB 206553, it was demonstrated that 5-HT in weaned pigs induced an 
endothelium-dependent relaxation response mediated by 5-HT2B receptors and a direct 
relaxation response by 5-HT7 receptors. However, these findings are in direct contrast to 
the response seen in slaughter-age pigs. In slaughter-age pigs, it was found that 
pulmonary artery vasorelaxation only is mediated by 5-HT2B receptors. These results 
indicate that as the pig ages, it acquires a greater population of 5-HT2B receptors that 
contribute to vasorelaxation more so than 5-HT7. While our current study only found a 
vasorelaxation response in mesenteric veins in response to L-694, 247 and BW 723C86, 
the findings of Jähnichen et al. (2005) provide insight into the responses observed. It is 
possible that as ruminants age, they too, rely more heavily on 5-HT2B than 5-HT7.  
Conclusions 
The findings of this study indicate that 5-HT2A is present in ruminal and 
mesenteric vasculature, plays a role in vasoconstriction, and could be influenced by ergot 
alkaloid exposure as has been demonstrated in peripheral blood vessels. In contrast, the 
5-HT1D and 5-HT2B receptor subtypes do not contribute to vasoconstriction in any blood 
vessel tested, but may be present in mesenteric veins and possibly contribute to 
vasorelaxation. Further research with 5-HT2A should be directed towards defining the 
relationship this receptor has with ergot alkaloids and associated vasoconstriction. 
Additionally, as this study was confined to mesenteric and ruminal vasculature, it may be 
possible to expand this study to include blood vessels in different anatomic locations. 
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Table 3.1. Agonists, function, and distribution of serotonin (5-HT) receptor subtypes. 
5-HT 
Receptor Agonist Receptor Function Distribution Sources 
5-HT1B 
CP 93129 
dihydrochloride 
Mood, Locomotion, 
Vasoconstriction 
 
CNS, 
Blood vessels 
 
Weinshank et 
al., 1992 
5-HT1D L-694, 247 
Locomotion, 
Vasoconstriction 
 
CNS, 
Blood vessels 
 
Hamel et al., 
1993 
5-HT2A TCB-2 
Appetite, 
Thermoregulation, 
Smooth muscle 
contractions, 
Vasodilation, 
Vasoconstriction 
CNS, 
Smooth 
muscles, 
Blood 
vessels, 
Platelets 
 
Morecroft and 
MacLean, 1998 
5-HT2B 
BW 723C86 
hydrochloride 
Appetite, 
Vasoconstriction, CV 
function, GI motility 
CNS, 
Blood 
vessels, 
CV system, 
GI tract 
 
Ullmer et al., 
1995 
5-HT4 BIMU-8 
Mood, Appetite, GI 
motility 
CNS, 
GI tract 
 
Dumuis et al., 
1989 
5-HT7 LP 44 
Behavior, 
Vasoconstriction 
CNS, 
Blood vessels 
Ullmer et al., 
1995 
CNS: central nervous system; CV: cardiovascular; GI: gastrointestinal. 
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Table 3.2. Log EC50 values in response to TCB-2 for mesenteric arteries (MA), 
mesenteric veins (MV), ruminal arteries (RA), and ruminal veins (RV). Values are 
expressed as the mean ± SEM. 1,2 
Myograph Treatment Vessel Log EC50, M 
TCB-2, M 
MA -4.79 ± 0.09 (7)3a 
MV -5.23 ± 0.09 (7)b 
RA -4.63 ± 0.11 (6)a 
RV -5.29 ± 0.11 (6)b 
a-bWithin a column for LogEC50, means without a common superscript differ (P < 0.05). 
1-Log EC50 = measure of the potency of a drug or agonist that induces a response midway 
(50%) between the baseline and maximum after a certain time of exposure; expressed as 
the molar concentration of the agonist, in this instance, 120 mM KCl. 
 
2EC50 values were only considered for vessels exposed to TCB-2 as TCB-2 was the only 
agonist that elicited a vasoconstrictive response. 
 
3Values in parentheses are the number of animals used in each experiment. 
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Figure 3.1 Chemical structure of the 5-HT2A agonist TCB-2 and mean contractile 
responses of mesenteric artery (MA), mesenteric Vein (MV), ruminal artery (RA), and 
ruminal vein (RV) to increasing concentrations of TCB-2. 
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Figure 3.2 Chemical structure of the 5-HT1B agonist CP 93129 dihydrochloride and 
mean contractile responses of mesenteric artery (MA), mesenteric Vein (MV), ruminal 
artery (RA), and ruminal vein (RV) to increasing concentrations of CP 93129 
dihydrochloride.  
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Figure 3.3 Chemical structure of the 5-HT7 agonist LP 44 and mean contractile responses 
of mesenteric artery (MA), mesenteric Vein (MV), ruminal artery (RA), and ruminal vein 
(RV) to increasing concentrations of LP 44.  
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Figure 3.4 Chemical structure of the 5-HT4 agonist BIMU-8 and mean contractile 
responses of mesenteric artery (MA), mesenteric Vein (MV), ruminal artery (RA), and 
ruminal vein (RV) to increasing concentrations of BIMU-8.  
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Figure 3.5 Chemical structure of the 5-HT2B agonist BW 723C86 and mean contractile 
responses of mesenteric artery (MA), mesenteric Vein (MV), ruminal artery (RA), and 
ruminal vein (RV) to increasing concentrations of BW 723C86.  
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Figure 3.6 Chemical structure of the 5-HT1D agonist L-694, 247 and mean contractile 
responses of mesenteric artery (MA), mesenteric Vein (MV), ruminal artery (RA), and 
ruminal vein (RV) to increasing concentrations of L-694,247.  
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CHAPTER FOUR: ASSESSMENT OF PEPTIDE TRANSPORTER 1 
INVOLVEMENT IN TRANSPORT OF ERGOT ALKALOIDS USING A CACO-2 
CELL MONOLAYER 
Introduction 
Tall-fescue (Lolium arundinaceum) is a cool-season, perennial grass that is often 
infected with a fungal endophyte (Epichloë coenophiala) that produces ergot alkaloids 
responsible for causing fescue toxicosis. Fescue toxicosis causes large production losses 
in the beef industry. The mechanisms underlying fescue toxicosis are intricate and not 
fully understood at this time. Little is known about the cellular mechanisms that lead to 
fescue toxicosis. Ergopeptines and lysergic acid amides bind to dopamine receptors and 
are thought to be one mechanism behind fescue toxicosis symptoms (Larson et al, 1999). 
α-Ergocryptine and bromocriptine are two ergopeptines that are dopamine receptor D2 
(D2R) agonists (Sibley and Creese, 1983). Activation of D2R stimulates a G-protein 
cascade, inhibiting adenylate cyclase and reducing cAMP inside the cell. Activation of 
D2R is thought to lead to many of the maladies affecting livestock consuming endophyte-
infected tall fescue. It has been hypothesized that ergot alkaloids are absorbed by the GI 
tract but there is limited evidence. Because ergopeptine alkaloids are charged in 
environments with a low pH, it is assumed that they are absorbed in the small intestine 
(Eckert et al., 1978).  Shapell and Smith (2005) assessed the movement of ergovaline and 
its isomer ergovalinine across human intestinal cells using Caco-2 cells. It was found that 
ergovaline and ergovalinine readily moved across Caco-2 cells without further 
metabolism and at similar rates at both 6 µM and 22 µM concentrations. However, it was 
not determined whether this movement was due to passive diffusion or active transport.  
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Recent studies suggest that transport proteins may play a role and contribute to 
EA toxicity (Settivari et al., 2009; Brown et al., 2009).  Intestinal absorption of numerous 
drugs and toxins can occur via passive diffusion (Eckert et al., 1978) but it is thought that 
carrier-mediated, or, active transport, may also contribute to drug absorption. Numerous 
transporters in the gastrointestinal tract have been identified. These include amino acid 
transporters, nucleotide transporters, and peptide transporters (Terada et al., 2004; 
Meredith et al., 2000). Peptide transporter 1 (PepT1) is an apically expressed solute 
carrier for peptides in the kidneys and brush border membrane of the intestines and acts 
in a proton dependent manner (Figure 4.1), (Adibi, 1997). PepT1 is responsible for 
dietary nitrogen uptake in the form of di- and tripeptides. It is pharmacologically and 
pharmaceutically relevant as it is hypothesized that PepT1 mediates drug transport 
because numerous drugs are hydrophilic in nature, limiting passive transport (Hironaka et 
al., 2008). PepT1 is a known transporter of ACE-inhibitors (Moore et al., 2000), 
thrombin inhibitors (Walter et al., 1995) and β-lactam antibiotics such as penicillins and 
cephalosporins (Brandsch, 2009; Hironaka et al., 2008; Terada et al., 1997; Bretschneider 
et al., 1999; Bailey et al., 2006). Because of the lactam ring present in ergorpeptams 
(Crews, 2015; Uhlig & Petersen, 2008) and peptide component of ergopeptides, it was 
hypothesized that ergot alkaloids are actively transported by peptide transporters. 
Various studies have targeted  transporters to improve bioavailability of drugs and 
nutrients (Cundy et al., 2004; Majumdar et al., 2004; Landowski et al., 2005). It is 
equally advantageous to target and identify  transporters, such as PepT1, to decrease the 
bioavailability of toxic agents such as ergot alkaloids. To understand how and if ergot 
alkaloids are absorbed in the small intestine, the objective of this study was to assess the 
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involvement of PepT1 in the transport of the peptide alkaloids ergotamine (ERT) and 
ergovaline (EXT), and the ergoline alkaloid lysergic acid (LSA) across a Caco-2 cell 
monolayer (Figure 4.2). 
Materials and Methods 
Cell Maintenance. Caco-2 cells (passage 18) were obtained from American Type 
Culture Collection (ATCC) (HTB-37; Rockville, MD) and maintained in Falcon flasks 
(passages 25 -28), (75 cm2, Becton-Dickinson, Bedford, MA) containing growth media 
consisting of Eagle’s minimum essential medium (EMEM) with 2 mM L-glutamine,  
(ATCC, Manassas, VA), 20 % fetal bovine serum (FBS) (reduced IgG; ATCC), and 1% 
antibiotic/ antimycotic solution (10,000 U mL-1 penicillin, 10 mg mL-1 streptomycin, and 
25 μg mL-1 amphotericin B; Sigma Chemical Co., St. Louis, MO). Humidified incubators 
were maintained at 37°C and 5% CO2. Cells were subcultured every five days 
(undifferentiated, subconfluent cells) using a trypsin (0.05%)-EDTA (0.02%) solution. 
For transport experiments, 1 × 105 cells (passages 25 – 28) were plated in cell 
culture inserts (0.4 µm pore size, 1 x 108 pores/cm2, 12 mm diameter, polyethylene 
terephthalate (PET); EMD Millipore Corporation, Billerica, MA) in 1 mL of the above 
growth media. Cell concentrations for seeding were determined by using a hand-held cell 
counter (Scepter 2.0; Millipore Sigma, Darmstadt, Germany). Inserts were placed in 
wells of a 12-well plate (Corning; #3513) containing 2 mL of the same media. Media in 
the apical side (upper chamber) and basolateral side (lower chamber) was replaced every 
other day.  
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Caco-2 Cell Monolayer Validation 
Cellular differentiation and confluent monolayer establishment were determined 
by examining monolayers through a microscope,  transepithelial electrical resistance 
(TEER) measurements, measuring sucrase activity, quantifying phenol red transport, and 
by assessing cytoxicity of experimental compounds. 
Transepithelial Electrical Resistance. Transepithelial electrical resistance 
(TEER) measurements were made using a TEER-meter (Millicell Electrical Resistance 
System; World Precision Instruments, Sarasota, FL) every other day. Electrodes were 
equilibrated in 0.15 mM NaCl for twenty-four hours before the initial measurements. 
Electrodes were sterilized for fifteen min in ethanol before measurements were taken. 
Measurements were performed within five min after taking culture plates out of the 
incubator to minimize temperature fluctuations. Electrodes were sterilized between plate 
measurements. To obtain a sample resistance, the unit area resistance (Ω * cm2) was 
calculated by multiplying the sample resistance by the effective area of the membrane 
(1.1 cm2 for 12-well Millicell inserts). Final TEER values were obtained after subtracting 
the resistance of the cell-free filter.  
Sucrase Activity. Sucrase activity increases as enterocytes differentiate and is 
considered a good indicator of Caco-2 cell differentiation. Release of glucose in the 
apical compartment was measured using the fluorescent Amplex Red Glucose/ Glucose 
Oxidase Assay Kit (Cat. No. A22189; Molecular Probes, Eugene, OR). Sucrase activity 
of cells was measured on day 7 and day 18 in triplicate. Cells were washed with 
phosphate buffered saline (PBS; No. P4417, Sigma) twice to remove any pre-existing 
glucose that could possibly interfere with the reaction. Rinsed cells were pre-incubated at 
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37°C for 60 min with 1 mL of PBS and sucrose solution in the apical well and 2 mL of 
PBS in the basolateral well. After the 1 hour incubation, 200 µL of sample was collected 
at time intervals of 2, 4, 6, and 8 min. Samples were incubated at room temperature 
protected from light, for fifteen min. Amplex Red/ UltraRed Stop Reagent (Cat. No. 
A33855; Molecular Probes, Eugene, OR) was added to the sample to terminate the 
fluorescence signal-generating reaction in the enzymatic assay. Sample tubes were 
vortexed for approximately 3 seconds and sample fluorescence was measured using a 
fluorometer (Qubit 2.0; Invitrogen; Cat. No. Q32866, Carlsbad, CA). 
Phenol Red Diffusion. Phenol red diffusion was used as a measure of cell 
monolayer integrity. Diffusion of phenol red was measured on day 7 and day 18 in 
triplicate. Culture media was removed from the apical and basolateral wells. Cells were 
washed with phenol red-free EMEM (Sigma Chemical Co.) twice, to ensure total removal 
of phenol red-containing growth media. One mL of phenol red containing growth media 
was placed in the apical insert and 2 mL of phenol red-free media was placed in the 
basolateral compartment. As a control, 2 mL of phenol red free and phenol red containing 
growth medium were incubated in wells with inserts. Cells were incubated at 37°C for 
150 min. Aliquots of 200 µL were removed from the apical and basolateral chambers and 
plated in a 96-well plate. Absorbances were determined using a microplate reader 
(Synergy HT, Biotek Instruments, Inc., Winooski, VT) set to read at a wavelength of 546 
nm using KC4 3.1 Rev 15 software (Biotek Instruments, Inc.). Absorbance values were 
corrected by subtracting the phenol red free absorbance values from the apical and basal 
phenol red absorbance values and percent diffusion was calculated using the formula: 
𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 𝑏𝑎𝑠𝑎𝑙 (𝑛𝑚)
𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 𝑏𝑎𝑠𝑎𝑙 (𝑛𝑚)+𝑐𝑜𝑟𝑟𝑒𝑐𝑡𝑒𝑑 𝑎𝑝𝑖𝑐𝑎𝑙 (𝑛𝑚) 𝑥 100. 
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Cytotoxicity. An alamar blue assay (Thermofisher; Cat No. DAL1100) was used 
to assess cytotoxicity by quantifying the reducing environment of cells. The reducing 
environment in the alamar blue assay measures resazurin (oxidized form; blue) to 
resorufin (reduced form; pink). Cells for toxicity experiments (passages 25 – 27) were 
plated at 5 x 104 cells/well in 96-well plates (Falcon, Becton-Dickinson, Bedford, MA), 
using phenol red EMEM (Sigma Chemical Co.) containing 20% FBS and 1% A/A. Cells 
were allowed to grow for 7 days to create a semi-differentiated monolayer. Cells were 
exposed to 100 µL of ERT, LSA, and EXT at concentrations of 100 μM, 10 μM, and 1 
μM with 10 µL of alamar blue for 12 hours. Controls consisted of a positive growth 
control containing cells, HBSS media, and alamar blue and a negative control that 
contained HBSS media and alamar blue but no cells. All treatments were conducted in 
triplicate. Readings were taken at 30, 90, 360, and 720 min at absorbances of A570 nm and 
A600 nm in a multi-mode microplate reader (Synergy HT, Biotek Instruments, Inc.) using 
KC4 3.1 Rev 15 software (Biotek Instruments, Inc.). To determine the percent reduction 
of resazurin to resorufin, the following calculations were used: 
1. % Reduced = CRED test well / COX negative control well 
2. % Reduced = (εOX) λ2 Aλ1 - COX(εOX) Aλ1 Aλ2 / (εRED) λ1 A’λ2 - COX(εRED) λ2 
A’λ1) x 100 
To calculate the percent difference in reduction between treated and control cells: 
3. (εOX) λ2 Aλ1 - (εOX) λ1 Aλ2 of test agent/ (εOX) λ2 A°λ1 - (εOX) λ1 A°λ2 of untreated 
positive growth control) x 100 
Where CRED = is the concentration of reduced alamar blue, COX is the oxidized form of 
alamar blue, εOX is the molar extinction coefficient of oxidized alamar blue, εRED is the 
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molar extinction coefficient of reduced alamar blue, A is test well absorbance, A’ is the 
absorbance of negative control wells, A° is the absorbance of positive growth control 
wells, λ1 is A570 nm, and λ2 is A600 nm. 
Preparation of Treatment Stocks 
 To make stock standards for cytotoxicity and transport experiments, 100 μM 
cephalexin hydrate (CEPH; C4895, Sigma Chemical Co.), a positive control for PepT1 
was prepared in phenol red free Hank’s balanced salt solution (HBSS, H8264, Sigma 
Chemical) modified with sodium bicarbonate (S5761, Sigma Chemical).  D-lysergic acid 
dihydrate (95%; Acros Organics, Geel, Belgium) and ergotamine D-tartrate (≥97% 
purity, #45510. Fluka, Sigma Chemical Co.) were weighed out. Ergotamine was brought 
up in solution with methanol and 100 μM standards of lysergic acid were prepared in 
80% (vol/vol) methanol acidified with 1.2x10-4 M acetic acid. Ergovaline was prepared in 
phenol red free HBSS and vacuum filtered. Analysis showed that filtering did not alter 
the concentration of ergovaline present in the media. Standards only containing 
cephalexin, ergotamine, lysergic acid, and ergovaline were further diluted to create 10 
μM and 1 μM stock standards. A solution of 0.5 mM nateglinide (NATE) (Cat. No. 4231, 
Tocris Bioscience, Minneapolis, MN), an inhibitor of PepT1, was prepared in 
dimethylsulfoxide (DMSO; 25-950-CQC, Mediated Corning, Manassas, VA), and 
brought to volume with media containing the experimental compounds. 
Transport Studies  
Experimental Treatment of Cells. Apical to basolateral transport studies were 
conducted 21 days post-plating when cells were fully differentiated. Growth media in the 
apical and basolateral compartments was removed. Cells were washed with Hank’s 
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balanced salt solution (HBSS) to remove traces of growth media. Media in the basolateral 
compartment was changed to 2 mL HBSS and media in the apical compartment was 
composed of 1 mL of HBSS containing 1 μM, 10 μM, or 100 μM of cephalexin, 
ergotamine, lysergic acid, and ergovaline in the presence or absence of 0.5 mM of 
nateglinide. Samples (200 μl) were collected from apical and basolateral compartments 
over a 12-hour period at 30, 60, 90, 180, 360, and 720 min. Samples that were 
immediately collected were stored in the dark at 4ºC until analysis. Remaining media in 
the apical and basolateral compartments was collected and stored at -20°C in amber vials 
(Waters, Product Number 600000669CV, Milford, MA).   
Liquid Chromatography-Mass Spectrometry. Aliquots of collected apical and 
basolateral media were thawed and diluted with 10% acetonitrile/water (Fisher Optima) 
so samples would fall within the range of standards and spiked with 20 µL of an internal 
standard, methysergide (MYS; Sigma Chemical, St Louis, MO). Inserts were thawed and 
200 µL of Millipore water was added to the tubes and tubes were sonicated for 5 min. A 
780 µL-aliquot of 10% acetonitrile was added to the tubes and tubes were centrifuged for 
15 seconds. Contents of the tubes were transferred to amber vials and spiked with 20 µL 
of MYS. Samples were analyzed by ultra-high pressure liquid chromatography (UPLC) 
tandem mass spectrometry (MS/MS) (Waters Acquity triple quadrupole (TQD) mass 
spectrometer (product info?). Chromatographic separations were obtained using a 
reverse-phase ultra-performance liquid chromatography (UPLC) column (Waters BEH 
C18, 1.7 µm, 2.1 mm x 150 mm). The mobile phase consisted of water containing 0.1% 
formic acid (solvent A; Fisher) and acetonitrile containing 0.1% formic acid (solvent B) 
in a linear gradient from 25% B to 75% B at a flow rate of 0.35 mL/min. The TQD 
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tandem mass spectrometer was operated in positive ion multiple reaction monitoring 
(MRM) with electrospray ionization (ESI) using nitrogen as the nebulizing gas and argon 
as the collision gas. Chromatograms are shown for CEPH (Figure 4.3a), ERT (Figure 
4.3b), EXT (Figure 4.3c), and LYS (Figure 4.3d) 
Statistical Analysis 
 All data were analyzed using SAS (SAS 9.3, SAS Inst. Inc., Cary, NC). Phenol 
red data was analyzed using PROC GLM and a multi-means comparison test with day as 
the independent variable and percent diffusion as the dependent variable. Sucrase activity 
was analyzed using a nested design with min nested in day. A one factor ANOVA was 
utilized with LSD measurements and a Tukey post hoc test. Transport data was analyzed 
using PROC GLM and an orthogonal polynomial contrast to determine the best fit of 
increases and decreases in the appearance of analyte in the apical and basolateral 
chambers. Interaction effects were analyzed with PROC GLM between apical chamber 
with and without inhibitor; basolateral chambers with and without inhibitor; apical 
chambers compared to the no cell control; and basolateral chambers compared to the no 
cell control. For comparisons of apical chambers and basolateral chambers, time x NATE 
effects, time effects, and NATE effects were analyzed. For comparisons with the no cell 
control, time x cell effects, time effects, and cell effects were analyzed. A Shapiro-Wilk 
and Bartlett’s test were used to determine normality of data. All values are expressed as 
the mean ± SEM. Results are considered significant if probabilities are P < 0.05, unless 
reported otherwise. 
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Results and Discussion  
Prior work by Shapell and Smith (2005) demonstrated that ergovaline was readily 
absorbed across a Caco-2 cell monolayer. This study elaborated on previous work by 
examining the intestinal absorption of ergotamine, ergovaline, and lysergic acid, 
specifically by the transporter, PepT1. All significance values for time x NATE, time, 
and NATE effects are listed in Tables 4A – D in  Appendix 1 and regression analyses for 
all tested compounds are listed in Table 4.1 All experimental wells (apical + inhibitor 
(AP+), apical without inhibitor (AP-), basolateral with inhibitor (BA+), and basolateral 
without inhibitor (BA-)) were compared to a no cell control (NCC) that were exposed to 
the same conditions that the other wells were exposed to for 21 days to determine if the 
cell layer or the support membrane in the insert influenced transport of CEPH, ERT, 
EXT, and LYS.  
Cephalexin is a typical substrate for PepT1 (Dantzig and Bergin, 1988; Yang et 
al, 1999) and was demonstrated to have a relatively high affinity (Km of 7.5 ± 2.8 mM) 
for PepT1 in intestinal segments of rats (Hironaka et al., 2008) and Caco-2 cells 
(Bretschneider et al., 1999). Therefore, cephalexin was used as a model in this study to 
demonstrate that PepT1 was functional in this system. To further show that PepT1 was 
functional in this study, it was inhibited using the hypoglycemic agent nateglinide. 
Nateglinide is a dipeptide-like drug in that it possesses a carboxyl group and peptide bond 
in its structure. It was demonstrated in Caco-2 cells that nateglinide inhibited the 
transport activity of both PepT1 and PepT2 , but nateglinide itself was not transported by 
these transporters (Terada et al, 2000).  
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Intestinal absorption of numerous compounds is mainly by passive diffusion, but 
it is also believed that numerous membrane transporters are involved. Due to the 
complexity and relationship between different modes of influx and efflux, exact 
mechanisms and actions of compound transport are vague. Dipeptides and tripeptides are 
taken up by cells by the low affinity H+/ peptide cotransporter PepT1. Because 
ergotamine and ergovaline have a tri-peptide component to their structure, it was 
hypothesized that PepT1 may be involved in their transport from the intestinal lumen to 
the blood. Lysergic acid was proposed as a potential toxic agent in fescue toxicosis (Hill, 
2005) and was later determined to be a product of rumen metabolism of ergopeptines 
(DeLorme et al., 2007). Therefore, lysergic acid is also a compound of interest regarding 
intestinal transport. Based on previous research that showed that lysergic acid and 
lysergol were transported across ruminal gastric tissues (Hill et al., 2001; Ayers et al., 
2009), it was hypothesized that lysergic acid may also be transported in intestinal tissues. 
Caco-2 Cell Monolayer Model Validation 
Microscopy. Various studies disagree with the use of Caco-2 cells at days 18 – 21. 
Some believe that cells in culture as early as 6 – 9 days postseeding should be used in 
experimental studies (Trotter and Storch, 1991). Other studies call for using cells that are 
30 days in culture (Thwaites et al., 1994). However, Briske-Anderson et al. (1997) 
concluded that Caco-2 cell monolayers were fully differentiated by days 15 – 18. Briske-
Anderson et al. (1997) found that at days 15 - 18, sucrase and alkaline phosphatase 
activity are at a maximum and that cell numbers are stabilized, indicating that cell 
proliferation is complete. Because of these characteristics, cell models at days 18 -21 
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postseeding were used for homogenous cell number, density, and enzymatic purposes in 
the current study. 
The degree of morphologic differentiation of Caco-2 cells grown in T75 cm2 
flasks was evaluated in Figure 4.4. Images of Caco-2 cells before seeding in wells were 
captured on days 1, 3, 7, 14, 18, and 21. Cells were undifferentiated on day 1 as seeding 
had just occurred. By day 3, cell nuclei were visible and cells were beginning to form 
monolayers. On days 7 and 14, cells were semi-differentiated, as full monolayers were 
present. The differentiation process occurs in a mosaic pattern meaning that some areas in 
cell culture will express fully differentiated cells as soon as days 12 to 14 while other 
areas will be less differentiated (Lea, 2015). By days 18 and 21, cells were fully 
differentiated and should, therefore, be fully polarized as indicated by TEER values. Cell 
layers should form a continuous barrier between the apical and basal compartment by day 
21 if growth in flasks is an indicator. This is in agreement with data presented by Briske-
Anderson et al. (1997).  
Transepithelial Electrical Resistance (TEER) Values. Transepithelial electrical 
resistance (TEER) measurements were recorded every other day beginning on day 2 
(undifferentiated) and ending on day 20 (fully differentiated) (Figure 4.5). Measured 
TEER values generally ranged from 100 to 550 Ω cm2 with lower values correlating to 
days early in culture and higher values correlating to later days in culture. Similar values 
were reported in Caco-2 cells and INT 407 cells by Ismail (1999) and Yamashita et al. 
(2002). These values are sufficient for transport studies as determined by Bohers et al. 
(2001), Nigsch et al. (2007), and Balimane and Chong (2005).  The TEER for cells used 
in experiments for CEPH, LSA, and EXT reached the maximum value at day 10 in 
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culture and TEER for the ERT experiment reached a maximum at day 12. The TEER 
values began to gradually decrease afterwards for all cells in culture before plateauing. 
The TEER values can be influenced by cell passage number, seeding density, temperature 
at the time measurements were made, and culture conditions. Usually, decreasing TEER 
values are indicative of cell death or poor monolayer formation. However, Derk et al. 
(2015) conducted a study for testing the effect of exposure nanoparticles on the lung 
alveolar epithelial barrier using the human lung epithelial cell line, Calu-3. They 
evaluated monolayer formation by measuring electrical resistance of cell monolayers and 
found that FBS concentration in culture medium greatly affected epithelial monolayer 
integrity. Each well was seeded at the same concentration (5.0 x 104 cells/well) with 
increasing concentrations of FBS (2%, 5%, 10%, and 15%). Lower concentrations (2% 
and 5%) resulted in significantly higher TEER values than those cells cultured in 10% 
and 15% FBS. Culture medium supplemented with 10% FBS showed consistent TEER 
values while medium containing 15% FBS demonstrated larger variation in TEER values. 
Yamashita et al. (2002) also observed variability of TEER values when cells were 
exposed to FBS. It was found that longer culture period did result in tighter monolayers. 
The maximum TEER value was reached within 5 days, but after 5 days in culture, 
monolayer integrity gradually decreased. It was also found that transporter activity was 
highest at days 5 and 6 in culture. To obtain the highest activity of the transporters P-gp 
and PepT1, Yamashita et al. (2002) developed a modified short-term protocol with FBS-
containing medium. Their results indicated that this simple modification allowed them to 
obtain monolayers with better barrier properties and transport activity equivalent to the 
21-day culture system. Therefore, the amount of supplemental FBS used in this study 
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(20%) and the length of time in culture may have led to the variation in TEER values. 
The TEER data in the current study indicate that a confluent monolayer was obtained and 
maintained up to day 21 and the transport study. 
Phenol Red Diffusion. Phenol red diffusion is a simple, non-destructive method 
of assessing the confluency of cell monolayers as culture media already contained phenol 
red. Cell monolayer integrity is verified by a lack of phenol red in the basolateral 
chamber. Diffusion of phenol red from the apical to the basal compartment was 
significantly lower (P < 0.0006) on day 18 with an average percent diffusion of 2.5% 
(Figure 4.6). Day 7 exhibited an increased amount of phenol red diffusion with an 
average of 21.5% diffusion. This is indicative that cell monolayers are confluent by day 
18 and agrees with previously measured TEER values. Ismail (1999) also used phenol red 
diffusion as a measure of monolayer confluency in Caco-2 cells and the HeLa derivative 
cell line INT 407. Diffusion in both cell lines was measured over a period of 20 days. On 
day 5, diffusion of phenol red was around 15%, lower than the value reported for day 7 in 
this study. On day 17, phenol red diffusion values had reached a constant of around 6%, 
higher than the value reported in the present study. The differences in the diffusion values 
obtained by Ismail (1999) may be a consequence of differing of membrane inserts used, 
cell line used, type of medium used (DMEM), and the amount of FBS supplemented 
(10%) compared to the current study. 
Sucrase Activity. Small intestine brush border enzymes are typically assayed 
using tissue homogenates, membrane preparations (Dahlqvist, 1968), or intact small 
intestinal preparations (Lee et al., 1998) with sucrase activity linearly increasing during 
cell differentiation (Galand, 1989). Therefore, it is considered a good indicator of Caco-2 
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cell differentiation (Van Beers et al., 1995). Sucrase is a catalyst that causes the 
hydrolysis of sucrose to glucose and fructose. It is generally measured from microvilli 
fractions or whole cell homogenates (Ferruzza et al., 2011). Figure 4.7 shows non-
significant differences between concentrations at min 2, 4, 6 and 8 within days 7 and 18. 
However, across days sucrase activity on day 18 was greater at all measured timepoints 
(P < 0.0001) than on day 7, indicating that cell monolayers were viable and intact. This is 
similar to the findings of Feruzza et al. (2011). Using a Caco-2 cell line, Feruzza et al. 
used a glucose assay kit to measure sucrase activity of cells growing on cell inserts. 
Sucrase activity was measured (nmol/mL) between 1 and 8 min on days 8, 15, and 21 in 
culture. Data showed linear increases as time went on, with activity being significantly 
higher (P < 0.01) on day 21 as compared to sucrase activity on days 8 and 15, consistent 
with current findings that the longer in culture, the higher the sucrase activity of cells. 
Based on physical morphology, TEER values, phenol red exclusion data, and, sucrase 
activity, the Caco-2 cells in culture for 21 days were confluent, exhibited sufficient 
monolayer integrity, and were differentiated and ready for ergot alkaloid transport 
studies. 
Cytotoxicity of Ergotamine, Ergovaline, and Lysergic Acid. An alamar blue 
assay was used to assess the toxicity of three different concentrations (1, 10, and 100 µM) 
of ergotamine, ergovaline, and lysergic acid on semi-differentiated Caco-2 cells. 
Resazurin is a blue colorimetric indicator that will reduce to a pink, fluorescent form, 
resorufin, in response to cellular metabolism. The intensity of the fluorescence produced 
is proportional to the amount of living cells and can be used to quantitatively measure 
toxicity and cell viability. Alamar blue is desirable as an indicator as it does not interfere 
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with the electron transport chain nor does it affect cell respiration and function like other 
redox indicators. Results were reported as percent reduction of the indicator resazurin and 
percent inhibition of Caco-2 cell growth. 
 Ergotamine. Reduction of resazurin to resorufin increased from 1 h to 3 h where 
it remained constant until the end of the experiment at 12 h in response to all three 
concentrations of ergotamine (Figure 4.8). At 6 h, there was an increase in reduction but 
it decreased to levels seen at 3 h by the end of the experiment at the 100 µM 
concentration level (Figure 4.8). Average reduction levels ranged from 45% to 56%, 
indicating that only half of resazurin was reduced to resorufin, which could indicate that 
only half of the available cells were living or functional. Ergotamine has been found to 
show a weak cytotoxic effect with a decline in viability to 80% in renal proximal tubule 
epithelial cells (Mulac and Humpf, 2011). Ergotamine cytotoxicity was assessed using a 
CCK-8 assay with concentrations ranging from 1 nM to 20 µM. Although effects were 
weak, a clear cytotoxic effect was observed in comparison to the control cells at the 
concentration range of 5 µM to 20 µM. A second experiment studying the impact of ergot 
alkaloids on the blood-brain barrier also showed that ergotamine had no impact on cell 
viability (Mulac et al., 2011). It is possible that reduction of resazurin was only at around 
50% because of the state the cells were in. As cells were at a semi-differentiated state in 
the current experiment, tight junctions would not be fully formed, nor would a cell 
monolayer be completely intact.  
 Lysergic Acid. Lysergic acid was not toxic to cells at concentration. At 1 h, 
reduction ranged from 41% to 51% (Figure 4.9). By hour 3, more than 100% reduction 
had been reached at the 100 µM and 10 µM levels and reduction was at 97% at the 1 µM 
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level. By the sixth hour, reduction was beyond 100% at all concentrations. There are few 
studies assessing the toxicity of lysergic acid on cells, but there are studies assessing 
other derivative lysergic acid amides. Ergotmetrine (ergonovine) is one such derivative. 
Documented previously regarding ergotamine toxicity, the study by Mulac and Humpf 
(2011) assessed the toxicity of ergometrine using the CCK-8 assay, LDH activity, and 
capase-3 activation. Ergometrine did not have any cytotoxic effects on RPTEC and was 
not taken up by the cells during uptake studies. Although ergometrine is a derivative of 
lysergic acid and toxicity was assessed in a different cell line, based on this information 
and the results of the alamar blue assay, it can be said that lysergic acid is not toxic to 
Caco-2 cells. 
 Ergovaline. Ergovaline in a tall fescue seed extract was not toxic to cells at the 1 
µM concentration. One hundred percent reduction was observed by hour 6 and cell 
growth was only inhibited by 7% at the first hour (Figure 4.10). Ergovaline at 10 µM and 
100 µM concentrations was toxic to semi-differentiated cells. Reduction of resazurin 
increased from the first hour for both concentration levels but reduction was the same 
from 3 h to the end of the experiment (Figure 4.10). The 100-µM concentration may have 
been more toxic than 10 µM ergovaline as the overall average inhibition of cell growth 
was 44% (56% viability) at the 100 µM and 30% (70% viability) at 10 µM. In a similar 
study using Caco-2 cells, ergovaline toxicity was assessed using mitochondrial succinate 
dehydrogenase activity, alamar blue (cytochrome oxidase activity), and DNA 
quantitation assays (Shapell, 2003). Concentrations of 10-11 to 10-4 M to Caco-2 cells and 
toxicity were assessed after 24 and 72 h of exposure on days 1, 8, and 18. It was 
determined that undifferentiated cells were the most sensitive to 10-4 M ergovaline. After 
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72 h, undifferentiated cells in all three assays had activities reduced to less than 10% of 
the control means. At day 11, ergovaline toxicity had decreased in semi-differentiated 
cells. By day 18, alamar blue activity decreased and no change in DNA occurred until 
after 72 h of exposure. These findings indicated that ergovaline toxicity was dependent 
on differentiation state and that ergovaline was not toxic to differentiated cells. Cells 
tested in this study were semi-differentiated and, it can therefore be assumed that cells 
were more sensitive to ergovaline on day 7, but were most likely resistant by the time 
transport studies were conducted at day 21 when cells were fully differentiated.  
Cellular Transport and Mass Spectrometry Analysis 
Insert, No Cell Control, and 1 µM Data. Cell monolayers were collected and the 
insert concentrations were analyzed to see if cells or the insert membrane contained 
accumulations of cephalexin, ergotamine, ergovaline, or lysergic acid; however, no 
significant concentrations were collected from inserts across any concentration. 
Therefore, this data was excluded from this study. Regarding the no cell control data, in 
Figure 4.11 the presence of cells in experimental wells appears to play a role in inhibiting 
transport of all compounds to the basolateral  chamber as compared to wells that do not 
contain cells. It can also be suggested that Nateglidine exacerbates this effect. As the 
effects noted in Figure 4.11 were similar in wells across all compounds at every 
concentration, data were not included. It should also be noted that due to the fact that the 
results from the 1 µM data were inconsistent and biologically irrelevant, these data were 
also omitted. 
Cephalexin and Lysergic Acid – 10 µM. At 10 µM cephalexin, there was some 
inhibition of 10 uM cephalexin and lysergic acid. A time effect (P = 0.002) and a NATE 
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effect (P= 0.02) were observed between CEPH AP+ chambers and CEPH AP- chambers. 
As time increased, the amount of CEPH in the both apical chambers decreased (Figure 
4.12). The chambers containing nateglinide had a greater mean percent recovery of 
cephalexin compared to that of CEPH AP- (P = 0.02) meaning that the inhibitor did 
allow for some inhibition of cephalexin transport overall; however, CEPH AP+ and 
CEPH AP- did not differ from each other from timepoint to timepoint (Figure 4.12). The 
10 µM concentration of cephalexin may have been inhibited by nateglinide, but this 
inhibition is not time dependent. 
At the 10 µM concentration level, the transport of lysergic acid was inhibited 
from 180 min onwards (Figure 4.13). A time x NATE interaction effect was observed (P 
= 0.01), indicating that both time and the presence of NATE affected the percent recovery 
obtained from the apical wells. As time increased, the concentration of lysergic acid 
present in the Lysergic acid AP- wells decreased linearly (P < 0.0001); however, the 
concentration of lysergic acid present in the LSA AP+ wells remained constant and 
concentrations did not differ from one another. There was also a time x NATE effect (P < 
0.0001) between the LSA BA+ and LSA BA-; as time increased the amount of lysergic 
acid in the basolateral compartment increased for cells not exposed to NATE; cells 
exposed to NATE had lower concentrations of lysergic acid present in the basolateral 
chamber and the amounts present did not differ from one another. A significant increase 
in lysergic acid in LSA BA- was not seen until the 180 min timepoint; from there the 
concentration increased from 2.8% recovery to 4.4% at the 360 min timepoint, and from 
4.4% to 6.2% recovery at the 720 min time point (Figure 4.13). These results indicate that 
inhibition of PepT1 reduced the apical to basal transport of lysergic acid. 
73 
 
Ergotamine and Ergovaline – 10 µM. At the 10 µM concentration level, NATE 
did not inhibit transport of 10 uM ergotamine.  A time effect was observed between ERT 
AP+ wells and ERT AP- wells; as time progressed, the concentration of ergotamine in 
both AP+ and AP- decreased (P = 0.0002) but there was no difference in concentrations 
of ergotamine present in the apical chambers of ERT AP+ or ERT AP-. A time x NATE 
interaction effect was reported between ERT BA+ wells and ERT BA- wells (P = 0.004); 
however, this only appears to be significant due to a large flux of ergotamine that was 
present at the 30 min timepoint (Figure 4.14). 
 At the 10 µM concentration level, a time effect (P < 0.0001) and a NATE effect 
(P = 0.01) are observed between EXT AP+ wells and EXT AP- wells (Figure 4.15). As 
time decreases, the concentration of ergovaline in both AP+ and AP- wells decreases with 
a corresponding increase in BA+ and BA- wells. Overall, there is a greater average 
percent recovery in the AP+ wells than the AP- wells (P = 0.01).  There is an effect of 
NATE present, but it is not time dependent. A time effect is present between EXT BA+ 
and BA- wells (P < 0.0001) but there are no differences in concentrations. Thus, NATE 
does appear to inhibit transport of ergovaline, but its effects are not exacerbated by time. 
Cephalexin and Lysergic Acid – 100 µM. At the 100-µM level, a NATE effect 
was observed between 100 uM CEPH AP+ and CEPH AP- (Figure 4.16). Cephalexin 
AP+ was only different from CEPH AP- up to the 90 min timepoint. At 90 – 180 min, 
NATE appears to lose it effectiveness and the concentrations of cephalexin in the AP+ 
and AP- chambers are the same. In the basolateral chambers with NATE as compared to 
CEPH BA-, there was a time effect and a NATE effect. There was an increase in the 
appearance on cephalexin in the basolateral chambers of both BA+ and BA- as time 
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progressed (P < 0.0001). However, the appearance of cephalexin in the BA+ chambers 
was less than that of the BA- (19% v 30%; P = 0.01), indicating that NATE inhibited 
overall transport of CEPH, but was not time dependent. The only difference in 
concentration was the 30 min timepoint. After 30 min, concentrations in the basolateral 
chambers were the same (Figure 4.16). Therefore, cephalexin transport may be inhibited 
by nateglinide overall but IT may lose its effectiveness over time. 
At the 100 µM concentration level, NATE inhibited the transport of 100 uM 
lysergic acid (Figure 4.17). A NATE effect was observed between LSA AP+ and LSA 
AP- (P = 0.001), suggesting that NATE does contribute to inhibition and retaining 
lysergic acid in the apical chamber. Lysergic acid AP- wells decreased in a linear fashion 
(Table 4.1; P = 0.01) while LSA AP+ does not decrease at all, staying the same across all 
timepoints. Wells containing NATE had a greater average percent recovery compared to 
LSA AP- wells (P = 0.01; Figure 4.17). As the concentration of lysergic acid is not 
different between AP+ and AP- until 180 min, it is plausible to assume that NATE needs 
time to take effect and that it may not reach its maximal effect until after 180 min. This is 
further evidenced by the findings in the basolateral chambers. A NATE effect (P = 0.01) 
was observed between LSA BA+ and LSA BA- with LSA BA- increasing quadratically 
(Table 4.1; P = 0.006). An average of 26% LSA was recovered in LSA BA- wells as 
compared to an average of 3% recovery in LSA BA+ chambers. LSA BA+ chambers 
contained lower concentrations of lysergic acid that did not differ from one another 
across time until the 720 min timepoint; concentrations in LSA BA+ and LSA BA- 
differed from the 360 min timepoint on. 
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Ergotamine and Ergovaline – 100 µM. There was a time x NATE effect (P = 
0.002) between ERT AP+ and ERT AP- wells (Figure 4.18). As time increased, the 
concentration of ergotamine decreased in the apical chamber. Although the concentration 
of ergotamine present AP+ wells decreased over time also, the presence of the inhibitor at 
180 min still resulted in a greater concentration of ergotamine in the AP+ compared to 
AP- at 180 min. There was a time x NATE effect (P < 0.0001) between ERT BA+ and 
ERT BA-. As time increased, the appearance of ergotamine in the basolateral chamber 
increased in both ergotamine BA- and ERT BA+; however, NATE appears to have 
inhibited the transport of ergotamine as the untreated wells had larger concentrations of 
ergotamine in the basolateral chamber than cells apically treated with NATE. ERT BA- 
and ERT BA+ did not begin to differ until 180 min, indicating that perhaps, the 
effectiveness of NATE increased as time progressed (Figure 4.18).  It can be concluded 
from these results that ergotamine transport is inhibited by nateglinide at the 100 µM 
concentration,  but it is time-dependent. 
A time effect and NATE effect are present between EXT AP+ and EXT AP- 
(Figure 4.19). As time progresses, there is a decrease in the concentration of ergovaline in 
both EXT AP+ and EXT AP- wells (P < 0.0001). Wells that contain NATE have a 
greater overall percent recovery of ergovaline compared to recovery of ergovaline in AP- 
(P < 0.0001). There appears to be inhibition of ergovaline transport by NATE but only 
until the 180 min timepoint. A time effect is present between EXT BA+ and EXT BA-; 
the amount of ergovaline present in the basolateral chamber increases as time progresses 
(P = 0.01). The concentration of ergovaline present in the EXT BA+ wells and EXT BA- 
wells does not differ (Figure 4.19). These results indicate that NATE may inhibit the 
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amount of ergovalinetransported from the apical to the basolateral chamber overall, but 
the NATE effect appears to have limit over time. 
Overall Findings 
It was determined that the CEPH-NATE model was an appropriate model to use 
regarding PepT1 inhibition as cephalexin transport was inhibited by NATE at two 
concentration levels, 10 µM and 100 µM. In the current study, ergotamine was 
transported across the cell monolayer, indicating that ergotamine may primarily be 
transported in the small intestine. Ergotamine does not appear to utilize PepT1 until it is 
at the highest concentration level (100 µM). However, inhibition is incomplete as 
transport is still occurring in chambers treated with nateglinide; transport by PepT1 may 
not be completely inhibited and could be working in tandem with another form, whether 
it be passive, active, or a combination. (Ganapathy et al., 1995). Evidence of such 
statements is provided in findings observed using porcine brain capillary endothelial cells 
(PBCECs) as a model of the human blood-brain barrier (Mulac et al., 2011). Mulac et al. 
(2011) were interested in the extent to which EA are able to cross the blood-brain barrier 
and their effects on barrier integrity. The alkaloids ergometrine, ergocristinine, 
ergotamine, ergocornine, α-ergocryptine, and ergosine were of primary interest as these 
were identified as the most relevant alkaloids regarding toxicity. All compounds contain 
an optically active carbon atom at the C-8 position and can form epimers under certain 
conditions including light, pH change, and temperature change. Ergometrine (ergoline 
alkaloid), ergocristine, and ergotamine (ergopeptine alkaloids) were chosen for 
permeability studies as cells exposed to these ergot alkaloids maintained barrier integrity 
after exposure. For permeability studies, 10 µM of ergotamine was used. It was found 
77 
 
that ergotamine does have the ability to reach the brain, but no active transport properties 
were identified for it or ergocristine. Within hours, both ergopeptides were able to cross 
the blood-brain barrier. Ergometrine was also able to cross the blood-brain barrier but it 
was determined that it moved via active transport and is a substrate for BCRP, or breast 
cancer resistant protein. Although the cells used in this study were a model for the blood-
brain barrier, the SI also has a high concentration of BCRP, which plays a role in 
intestinal absorption. As ergometrine is a derivative of lysergic acid, it may be suggested 
that lysergic acid is not only transported by PepT1. This aligns with the results of lysergic 
acid transport at 10 µM and 100 µM as transport to the basolateral chamber was not 
completely inhibited, even in the presence of nateglinide, indicating that another 
transporter or form of transport is involved. 
Because cephalexin, ergovaline, and lysergic acid transport was reduced by 
nateglinide at the 10 µM and 100 µM concentration levels, it can be concluded that 
PepT1 plays some part in transport of ergot alkaloids from the lumen to the blood. Based 
on the results of the alamar blue assay, neither ergovaline nor lysergic acid was toxic by 
hour 12 to fully differentiated cells. It cannot be ruled out that passive transport or 
another transporter could be working in tandem with PepT1 as inhibition was not 
complete for any of the compounds at the 10 µM and 100 µM concentration levels, 
including the model compound cephaleexin. As demonstrated in rat intestinal segments, 
PepT1 substantially contributed to oral absorption of cephalexin, but the function of 
PepT1 could be compensated by passive diffusion if cephalexin were presented at a 
therapeutic dose (Hironaka et al., 2008).  
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Ergovaline-containing tall fescue seed extract was shown to be non-toxic at the 1 
µM concentration level and was considered non-toxic at higher concentrations in 
differentiated cells (although, in this study, it was toxic at the semi-differentiated state) 
based on results of the alamar blue cytotoxicity assay and previously conducted 
experiments. It was observed in this experiment that the concentrations 10 and 100 µM of 
ergovaline do move across the cell monolayer in the presence and absence of NATE, but 
concentrations of ergovaline are less in apical wells exposed to nateglinide. This indicates 
that ergovaline most likely uses PepT1, although inhibition of transport did not persist 
over the 12-hour time period. Similar, to ergotamine, it may also use a secondary form of 
transport to move across the cell monolayer. A similar experiment was conducted using a 
Caco-2 cell model to evaluate the movement of ergovaline and its isomer ergovalanine 
across the intestinal barrier to establish a route of dietary absorption (Shappell and Smith, 
2005). A pre-equilibrated ergovaline and ergovalinine mixture (60:40 ratio) at two 
concentrations (6 µM and 22 µM) was added to the apical compartment of cell inserts. 
Extracted media was assessed by high performance liquid chromatography. Active 
transport was not evaluated in this study, but it was determined that ergovaline and 
ergovalinine readily crossed Caco-2 cells at similar rates. Similar to this study, cells did 
slow the transport of ergovaline to the basolateral chamber. In this study, 100% recovery 
was not achieved for most of the compounds.  
 Anatomic location, route of compound administration, and physiological 
properties play a role in how compounds are transported and absorbed. Hill et al. (2004) 
evaluated whether transport of alkaloids was a passive or active process depending on the 
location in gastric tissues. Hill et al. (2004) suggested that alkaloid transport was an 
79 
 
active process in ruminant gastric tissues. This study differed in that ergoline and 
ergopeptide alkaloid transport was studied in isolated sheep gastric tissues, specifically 
reticular, ruminal, and omasal tissues. Ruminal and omasal tissues were removed, placed 
in parabiotic chambers, and exposed to equimolar concentrations of lysergic acid, 
lysergol, ergonovine, ergotamine, and ergocryptine. Tissues were incubated for 240 min 
and analyzed by competitive ELISA and freeze-dried serosal Kreb’s Ringer phosphate 
solution containing alkaloids was analyzed using high-pressure liquid chromatography. 
Ruminal tissue had greater alkaloid transport than omasal tissues due its surface area. The 
ruminal posterior sac had the greatest potential for alkaloid transport and the reticular 
tissues displayed the smallest amount of alkaloid transport. Similar to the findings of this 
study, lysergic acid was transported actively. Not only was lysergic acid and lysergol 
transported across omasal tissues, they were transported in larger quantities than the 
ergopeptine alkaloids, especially in omasal tissues. Of the alkaloids tested, lysergic acid 
had the greatest concentration in serosal chamber regardless of tissue type. These results 
indicated that simple ergoline alkaloids, such as lysergic acid and lysergol, were more 
likely to cross digestive barriers than ergopeptine alkaloids, such as ergotamine and 
ergovaline. Ayers et al. (2009) confirmed these findings by observing that lysergic acid 
was transported in greater quantities than ergovaline in both ruminal and omasal tissues. 
It was demonstrated by Hill et al. (2004) that ergotamine and ergocryptine had the least 
affinity for alkaloid transport among all tissues, with reticular tissues transporting the 
least amount of tissues  
In the current study, it appears as though the ergoline, lysergic acid, and the 
ergopeptides, ergovaline and ergotamine, move readily across a cell layer representing 
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the small intestine. They may use the transporter PepT1, but it is highly plausible that this 
is not the only form of transport available to ergot alkaloids. Although both ergovaline 
and ergotamine were readily absorbed, ergotamine requires a greater concentration (100 
µM) to be transported when compared to ergovaline, at which transport begins at 10 µM. 
This indicates that ergovaline may be more readily absorbed and be available in the blood 
sooner than ergotamine, possibly playing a larger part in symptoms of fescue toxicosis 
than ergotamine. Lysergic acid was also readily transported at the same concentrations as 
ergovaline, indicating that, it too, may play a larger role in fescue toxicosis symptoms 
than ergotamine, as previously suggested.  
Conclusions 
 Ergotamine and lysergic acid were not toxic to semi-differentiated cells. High 
concentrations of ergovaline in a seed extract was toxic to semi-differentiated cells. 
Ergotamine transport was not inhibited by nateglinide until the 100 µM concentration 
level. This indicates that apical transport of ergotamine across an epithelial barrier may 
use alternative protein transporters, passive diffusion, or a combination of transport 
modes. It is also plausible that it does not play as large a role in toxicosis symptoms as 
lysergic acid and ergovaline. Cephalexin, lysergic acid, and ergovaline transport was 
reduced by the presence of nateglinide at the 10 µM and 100 µM concentration levels. 
This provides further evidence that lysergic acid and ergovaline are involved in some 
facet of fescue toxicosis. Further work should focus on identifying whether other forms 
of transport in the small intestine play a role in transport of ergot alkaloids to areas 
outside of the GI tract. It would also be ideal to conduct similar studies with these 
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compounds using harvested tissues or an animal model. Finally, an inhibition study needs 
to be conducted to assess the affinity of these compounds for PepT1. 
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Table 4.1. Orthogonal polynomial contrast regressions of cephalexin (CEPH), 
ergotamine (ERT), ergovaline (EXT), and lysergic acid (LSA). 
Compound Concentration (µM) AP+
1 AP- BA+ BA- 
CEPH 
1 
Linear; 
< 0.0001 
 
Linear; 
0.0005 
Quadratic; 
0.02 
Quadratic; 
0.04 
10 
Linear; 
0.01 
 
Linear; 
0.003 
Linear; 
0.009 
Linear; 
0.0006 
100 
Linear; 
0.008 
 
-2 Linear; 
0.0001 
Quadratic; 
0.03 
ERT 
1 
Quadratic; 
0.0001 
- Quartic; 
0.002 
 
- 
10 
Quadratic; 
< 0.0001 
Linear; 
0.001 
Cubic; 
0.004 
 
Linear; 
0.005 
100 
Linear; 
0.0012 
Linear; 
< 0.0001 
 
Quartic; 
0.003 
- 
EXT 
1 - Quadratic; 0.02 
- - 
10 
Linear; 
0.004 
 
- Quadratic; 
0.03 
Linear; 
< 0.0001 
100 
Linear; 
< 0.0001 
 
Linear; 
0.0006 
- Quadratic; 
0.0007 
LSA 
1 
Quadratic; 
0.0006 
 
Linear; 
< 0.0001 
- - 
10 
Linear; 
< 0.0001 
Linear; 
< 0.0001 
 
Linear; 
< 0.0001 
Quadratic; 
0.02 
100 - Linear; 0.01 
- Quadratic; 
0.006 
1AP+: apical chamber with inhibitor; AP-: apical chamber without inhibitor; BA+ 
basolateral chamber with inhibitor; BA-: basolateral chamber without inhibitor 
2 Dashes show that there was no regression pattern present. 
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Figure 4.1 Peptide transporter 1 cellular mechanism in intestinal enterocytes 
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Figure 4.2 Structures of A. cephalexin (CEPH), B. ergotamine (ERT), C. lysergic acid 
(LSA), D. ergovaline extract (EXT), and E. nateglinide (NATE). 
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Figure 4.3a Chromatogram of Cephalexin (CEPH) 
 
 
Figure 4.3b Chromatogram of ergotamine (ERT) 
 
 
 
 
cephalexin 50uM (2x of 100uM) +MYS-20 HBSS- 5x 
Time
1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00 5.50 6.00 6.50 7.00 7.50 8.00 8.50 9.00 9.50
%
0
100
1.50 2.00 2.50 3.00 3.50 4.00 4.50 5.00 5.50 6.00 6.50 7.00 7.50 8.00 8.50 9.00 9.50
%
0
100
CEF-23-50uMx 2: MRM of 2 Channels ES+ 
348.25 > 158.01 (CEF)
3.54e6
5.01
348.3
CEF-23-50uMx 1: MRM of 1 Channel ES+ 
354.2 > 237.1 (MYS)
2.67e4
5.60
354.2
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Figure 4.3c Chromatogram of ergovaline seed extract (EXT) 
 
Figure 4.3d Chromatogram of lysergic acid (LSA)
LSA-50uM - MYS 20nM HBSS-5x jg
Time
1.20 1.40 1.60 1.80 2.00 2.20 2.40 2.60 2.80 3.00 3.20 3.40 3.60 3.80 4.00 4.20 4.40 4.60 4.80 5.00
%
0
100
1.20 1.40 1.60 1.80 2.00 2.20 2.40 2.60 2.80 3.00 3.20 3.40 3.60 3.80 4.00 4.20 4.40 4.60 4.80 5.00
%
0
100
LSA-50-0412-1 1: MRM of 2 Channels ES+ 
269.2 > 254.1 (LSA)
4.40e5
2.23
269.2
LSA-50-0412-1 2: MRM of 1 Channel ES+ 
354.2 > 237.1 (MYS)
5.10e3
3.24
354.2
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Figures 4.4a -f Images of Caco-2 cells at: A: day 1, B: day 3, C: day 7, D: day 14, E. day 
18, and day 21 at 100X magnification 
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Figure 4.5 Changes in TEER values across Caco-2 cell monolayers before treatment with 
cephalexin, ergotamine, ergovaline, and lysergic acid. 
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Figure 4.6 Phenol red exclusion: day 7 v. day 18 diffusion; Data are expressed as the 
means ± standard error from four different experiments and were analyzed using a 
multiple mean comparisons test. Means with different letters are significantly different (P 
< 0.05). 
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Figure 4.7 Sucrase activity of Caco-2 cells on day 7 and day 18. Data are expressed as 
the means ± standard error from four different experiments and were analyzed by one-
way ANOVA followed by pairwise comparison test, and Tukey post hoc test (P < 0.05). 
 
 
Figure 4.8 Percent reduction of resazurin to resorufin in the presence of different 
concentrations of ergotamine (ERT) over time. Concentrations are expressed as molar 
(M) and represent 10-6 M, 10-5 M, and 10-4 M. 
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Figure 4.9 Reduction of resazurin to resorufin in the presence of different concentrations 
of lysergic acid (LSA) over time. Concentrations are expressed as molar (M) and 
represent 10-6 M, 10-5 M, and 10-4 M. 
 
 
Figure 4.10 Reduction of resazurin to resorufin in the presence of different concetrations 
of ergovaline (EXT) over time. Concentrations are expressed as molar (M) and represent 
10-6 M, 10-5 M, and 10-4 M. 
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Figure 4.11 Percent recovery of 100 µM of lysergic acid (LSA) in wells with and 
without 0.5 mM nateglinide (NATE) compared to the no cell control (NCC). AP- (Apical 
chamber without NATE) and AP+ (apical chamber treated with NATE. Values are 
expressed as the mean ± SEM. 
 
 
Figure 4.12 Transport of 10 µM of cephalexin (CEPH) in wells with and without 0.5 mM 
nateglinide (NATE). AP- (Apical chamber without NATE), BA- (Basolateral chamber 
without NATE), AP+ (apical chamber treated with NATE), and BA+ (Basolateral 
chamber treated with NATE). Values are expressed as the mean ± SEM. 
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Figure 4.13 Transport of 10 µM of lysergic acid (LSA) in wells with and without 0.5 
mM nateglinide (NATE). AP- (Apical chamber without NATE), BA- (Basolateral 
chamber without NATE), AP+ (apical chamber treated with NATE), and BA+ 
(Basolateral chamber treated with NATE). Values are expressed as the mean ± SEM. 
 
 
Figure 4.14 Transport of 10 µM of ergotamine (ERT) in wells with and without 0.5 mM 
nateglinide (NATE). AP- (Apical chamber without NATE), BA- (Basolateral chamber 
without NATE), AP+ (apical chamber treated with NATE), and BA+ (Basolateral 
chamber treated with NATE). Values are expressed as the mean ± SEM. 
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Figure 4.15 Transport of 10 µM of ergovaline (EXT) in wells with and without 0.5 mM 
nateglinide (NATE). AP- (Apical chamber without NATE), BA- (Basolateral chamber 
without NATE), AP+ (apical chamber treated with NATE), and BA+ (Basolateral 
chamber treated with NATE). Values are expressed as the mean ± SEM. 
 
 
Figure 4.16 Transport of 100 µM of cephalexin (CEPH) in wells with and without 0.5 
mM nateglinide (NATE). AP- (Apical chamber without NATE), BA- (Basolateral 
chamber without NATE), AP+ (apical chamber treated with NATE), and BA+ 
(Basolateral chamber treated with NATE). Values are expressed as the mean ± SEM. 
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Figure 4.17 Transport of 100 µM of lysergic acid (LSA) in wells with and without 0.5 
mM nateglinide (NATE). AP- (Apical chamber without NATE), BA- (Basolateral 
chamber without NATE), AP+ (apical chamber treated with NATE), and BA+ 
(Basolateral chamber treated with NATE). Values are expressed as the mean ± SEM. 
 
 
Figure 4.18 Transport of 100 µM of ergotamine (ERT) in wells with and without 0.5 mM 
nateglinide (NATE). AP- (Apical chamber without NATE), BA- (Basolateral chamber 
without NATE), AP+ (apical chamber treated with NATE), and BA+ (Basolateral 
chamber treated with NATE). Values are expressed as the mean ± SEM. 
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Figure 4.19 Transport of 100 µM ergovaline (EXT) in wells with and without 0.5 mM 
nateglinide (NATE). AP- (Apical chamber without NATE), BA- (Basolateral chamber 
without NATE), AP+ (apical chamber treated with NATE), and BA+ (Basolateral 
chamber treated with NATE). Values are expressed as the mean ± SEM. 
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CHAPTER FIVE: SUMMARY AND CONCLUSIONS 
 Animals grazing on endophyte-positive tall fescue consume ergot alkaloids, 
leading to the condition known as fescue toxicosis. Symptoms include failure to thrive, 
reproductive failure, lack of appetite, reduced ability to regulate body temperature, and 
necrosis of appendages. It is thought that source of these symptoms may be due to 
vasoconstriction of peripheral tissues. However, vasoconstriction of core body vessels 
could also explain the appearance of symptoms. The mechanism or mechanisms of 
toxicity are still vague and have not completely identified. Nor has the causative agent 
been conclusively determined. It is generally thought that ergovaline is the causative 
agent of fescue toxicosis but there is also evidence that lysergic acid may also play a role 
in the disease mechanism. 
There is not much available information about the metabolism of ergot alkaloids 
in ruminants, but that the ergopeptines are excreted through the bile and ergolines are 
excreted through the urine in nonruminant animals. In ruminant animals, it has been 
demonstrated that ergot alkaloids have the ability to cross ruminal and omasal tissues, 
although ergolines pass at a greater concentration. It has also been demonstrated that 
ergovaline is able to readily pass across Caco-2 cell monolayers used as model of the 
small intestine. From this evidence, it could be suggested that ergot alkaloids may pass 
across the small intestine and affect tissues and organs located distally to the small 
intestine. 
The first experiment in this study was designed to identify the serotonin 
populations in mesenteric and ruminal vessels as ergot alkaloids are similar in structure to 
serotonin and may bind to the same receptors used by serotonin. Results from this 
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experiment indicated that the receptor 5-HT2A is present in ruminal and mesenteric 
vasculature as a contractile response was observed as concentrations of the agonist 
increased.  Previous work has indicated that 5-HT2A is influenced by ergot alkaloid 
exposure. Further, 5-HT1D and 5-HT2B may play a role in vasorelaxation, as a relaxation 
response was observed in response to their respective agonists.  
The second experiment focused on PepT1 transport of the ergot alkaloids 
ergotamine, ergovaline, and lysergic acid in the small intestine using a Caco-2 cell 
monolayer as a model. Because the chosen alkaloids have peptide-like structures, PepT1 
was specifically the transporter of interest as its role in the small intestine is to transport 
dietary dipeptides and tripeptides. Cephalexin was used as the model compound because 
it is a known substrate of PepT1. Compounds were inhibited by the nonsulfonylurea 
secretagogue, nateglinide. As intestinal transport is dependent on the integrity of cell 
monolayers and tight junctions, it was necessary to assess compound toxicity and monitor 
monolayer integrity through the experiment. This was done using an alamar blue 
cytotoxicity assay, measuring transepithelial electrical resistance values, conducting a 
phenol red diffusion assay, and monitoring sucrose levels in the apical and basolateral 
chambers. All data indicated that ergovaline, lysergic acid, and ergotamine were non-
toxic once cells were differentiated and that the cell monolayers were intact up to the 
time that transport studies were conducted. The results indicated that all compounds were 
transported at all timepoints across all concentrations. However, 10 and 100 μM 
cephalexin, ergovaline, and lysergic acid transport were inhibited by nateglinide, 
indicating that PepT1 is involved in the transport of these compounds. Ergotamine 
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transport was also inhibited at the highest concentration level but inhibition was 
incomplete at the lower concentrations evaluated.  
Previous research has indicated that ergovaline is the causative agent of fescue 
toxicosis. Other research has determined that lysergic acid may play as much a role as 
ergovaline in the disease state. In this study, we examined the role of PepT1 in ergot 
alkaloid transport across the small intestine. PepT1 may play a role in the transport of 
peptide-like alkaloids and the loline-types, but it cannot be readily confirmed as the only 
form of ergot alkaloid transport in the small intestine until further research is conducted. 
Although ergotamine was transported by PepT1 through the cell monolayer at 100 µM, 
based on these transport data it may not play as significant a role as the more readily 
transported lysergic acid and ergovaline in manifestation of symptoms of fescue 
toxicosis. This means that lysergic acid and ergovaline could reach the blood sooner than 
ergotamine and could have far-reaching effects in tissues and organs distal to their 
original absorption site. Furthermore, because lysergic acid and ergovaline are absorbed 
more readily, it is possible that these two alkaloids could contribute to vasoconstriction in 
the peripheral, ruminal, and mesenteric vasculature by binding to 5-HT receptors. 
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APPENDIX I 
Table 4A Interaction and main effects of apical chambers + nateglinide v apical 
chambers without nateglinide exposed to cephalexin and basolateral chambers + 
nateglinide v basolateral chambers without nateglinide exposed to cephalexin. P-values 
of less than 0.05 are considered significant. 
Compound Concentration (µM) Chamber 
Time 
effect 
Nateglinide 
effect 
Time x 
nateglinide 
interaction 
Cephalexin 
1 AP1  < 0.0001 0.6 0.9 
1 BA2  < 0.0001 0.04 0.6 
10 AP 0.002 0.02 0.9 
10 BA 0.001 0.1 0.4 
100 AP 0.1 0.009 0.1 
100 BA 0.0001 0.010 0.3 
1AP – apical chamber 
2BA- basolateral chamber 
Table 4B Interaction and main effects of apical chambers + nateglinide v apical 
chambers without nateglinide exposed to ERT and basolateral chambers + nateglinide v 
basolateral chambers without NATE exposed to ERT. P-values of less than 0.05 are 
considered significant 
Compound Concentration 
(µM) 
Chamber Time 
effect 
Nateglinide 
effect 
Time x 
nateglinide 
interaction 
Ergotamine 
1 AP1 0.0001 < 0.0001 0.02 
1 BA2  < 0.0001 0.0001 0.2 
10 AP 0.0002 0.1 0.09 
10 BA 0.07 0.03 0.004 
100 AP 0.0001 < 0.0001  0.002 
100 BA  < 0.0001 < 0.0001 < 0.0001 
1AP – apical chamber 
2BA- basolateral chamber 
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Table 4C Interaction and main effects of apical chambers + nateglinide v apical 
chambers without nateglinide exposed to ergovaline and basolateral chambers + 
nateglinide v basolateral chambers without nateglinide exposed to ergovaline. P-values of 
less than 0.05 are considered significant 
Compound Concentration 
(µM) 
Chamber Time 
effect 
Nateglinide 
effect 
Time x 
nateglinide 
interaction 
Ergovaline 
1 AP1 0.053 0.01  0.04 
1 BA2 0.3 0.3 0.5 
10 AP  < 0.0001 0.01 0.4 
10 BA  < 0.0001 -0.06 0.7 
100 AP  <0.0001 <0.0001 0.3 
100 BA  < 0.0001 0.9 0.2 
1AP – apical chamber 
2BA- basolateral chamber 
Table 4D Interaction and main effects of apical chambers + nateglinide v apical 
chambers without nateglinide exposed to lysergic acid and basolateral chambers + 
nateglinide v basolateral chambers without nateglinide exposed to lysergic acid. P-values 
of less than 0.05 are considered significant. 
Compound Concentration 
(µM) 
Chamber Time 
effect 
Nateglinide 
effect 
Time x 
nateglinide 
interaction 
Lysergic 
acid 
1 AP1 < 0.0001 0.2 0.09 
1 BA2 0.5 1.0 0.3 
10 AP < 0.0001 0.0001  0.01 
10 BA < 0.0001 < 0.0001  < 0.0001 
100 AP 0.1 0.001 0.4 
100 BA 0.3 0.01 0.3 
1AP – apical chamber 
2BA- basolateral chamber 
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